false 2025 Q3 0000072331 October 31 P1Y xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure ndsn:segment 0000072331 2024-11-01 2025-07-31 0000072331 2025-08-18 0000072331 2025-05-01 2025-07-31 0000072331 2024-05-01 2024-07-31 0000072331 2023-11-01 2024-07-31 0000072331 2025-07-31 0000072331 2024-10-31 0000072331 us-gaap:CommonStockMember 2024-10-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0000072331 us-gaap:RetainedEarningsMember 2024-10-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-31 0000072331 us-gaap:TreasuryStockCommonMember 2024-10-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-01-31 0000072331 us-gaap:TreasuryStockCommonMember 2024-11-01 2025-01-31 0000072331 2024-11-01 2025-01-31 0000072331 us-gaap:RetainedEarningsMember 2024-11-01 2025-01-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-11-01 2025-01-31 0000072331 us-gaap:CommonStockMember 2025-01-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0000072331 us-gaap:RetainedEarningsMember 2025-01-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-31 0000072331 us-gaap:TreasuryStockCommonMember 2025-01-31 0000072331 2025-01-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2025-02-01 2025-04-30 0000072331 us-gaap:TreasuryStockCommonMember 2025-02-01 2025-04-30 0000072331 2025-02-01 2025-04-30 0000072331 us-gaap:RetainedEarningsMember 2025-02-01 2025-04-30 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-02-01 2025-04-30 0000072331 us-gaap:CommonStockMember 2025-04-30 0000072331 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0000072331 us-gaap:RetainedEarningsMember 2025-04-30 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-30 0000072331 us-gaap:TreasuryStockCommonMember 2025-04-30 0000072331 2025-04-30 0000072331 us-gaap:AdditionalPaidInCapitalMember 2025-05-01 2025-07-31 0000072331 us-gaap:TreasuryStockCommonMember 2025-05-01 2025-07-31 0000072331 us-gaap:RetainedEarningsMember 2025-05-01 2025-07-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-05-01 2025-07-31 0000072331 us-gaap:CommonStockMember 2025-07-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2025-07-31 0000072331 us-gaap:RetainedEarningsMember 2025-07-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-31 0000072331 us-gaap:TreasuryStockCommonMember 2025-07-31 0000072331 us-gaap:CommonStockMember 2023-10-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0000072331 us-gaap:RetainedEarningsMember 2023-10-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-31 0000072331 us-gaap:TreasuryStockCommonMember 2023-10-31 0000072331 2023-10-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2023-11-01 2024-01-31 0000072331 us-gaap:TreasuryStockCommonMember 2023-11-01 2024-01-31 0000072331 2023-11-01 2024-01-31 0000072331 us-gaap:RetainedEarningsMember 2023-11-01 2024-01-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-11-01 2024-01-31 0000072331 us-gaap:CommonStockMember 2024-01-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2024-01-31 0000072331 us-gaap:RetainedEarningsMember 2024-01-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-31 0000072331 us-gaap:TreasuryStockCommonMember 2024-01-31 0000072331 2024-01-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2024-02-01 2024-04-30 0000072331 us-gaap:TreasuryStockCommonMember 2024-02-01 2024-04-30 0000072331 2024-02-01 2024-04-30 0000072331 us-gaap:RetainedEarningsMember 2024-02-01 2024-04-30 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-02-01 2024-04-30 0000072331 us-gaap:CommonStockMember 2024-04-30 0000072331 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0000072331 us-gaap:RetainedEarningsMember 2024-04-30 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-30 0000072331 us-gaap:TreasuryStockCommonMember 2024-04-30 0000072331 2024-04-30 0000072331 us-gaap:AdditionalPaidInCapitalMember 2024-05-01 2024-07-31 0000072331 us-gaap:TreasuryStockCommonMember 2024-05-01 2024-07-31 0000072331 us-gaap:RetainedEarningsMember 2024-05-01 2024-07-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-05-01 2024-07-31 0000072331 us-gaap:CommonStockMember 2024-07-31 0000072331 us-gaap:AdditionalPaidInCapitalMember 2024-07-31 0000072331 us-gaap:RetainedEarningsMember 2024-07-31 0000072331 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-31 0000072331 us-gaap:TreasuryStockCommonMember 2024-07-31 0000072331 2024-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2025-05-01 2025-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2024-05-01 2024-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2024-11-01 2025-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2023-11-01 2024-07-31 0000072331 ndsn:AtrionCorporationMember 2024-08-21 2024-08-21 0000072331 ndsn:A364DayTermLoanMember 2024-08-21 0000072331 ndsn:AtrionCorporationMember 2024-08-21 0000072331 ndsn:AtrionCorporationMember us-gaap:TradeNamesMember 2024-08-21 0000072331 ndsn:AtrionCorporationMember us-gaap:TradeNamesMember ndsn:AcquisitionsInTwoThousandTwentyThreeMemberMember 2024-08-21 2024-08-21 0000072331 ndsn:AtrionCorporationMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-08-21 0000072331 ndsn:AtrionCorporationMember us-gaap:TechnologyBasedIntangibleAssetsMember ndsn:AcquisitionsInTwoThousandTwentyThreeMemberMember 2024-08-21 2024-08-21 0000072331 ndsn:AtrionCorporationMember us-gaap:CustomerRelationshipsMember 2024-08-21 0000072331 ndsn:AtrionCorporationMember us-gaap:CustomerRelationshipsMember ndsn:AcquisitionsInTwoThousandTwentyThreeMemberMember 2024-08-21 2024-08-21 0000072331 ndsn:MedicalFluidSystemsMember 2024-11-01 2025-07-31 0000072331 us-gaap:LandMember 2025-07-31 0000072331 us-gaap:LandMember 2024-10-31 0000072331 us-gaap:LandImprovementsMember 2025-07-31 0000072331 us-gaap:LandImprovementsMember 2024-10-31 0000072331 us-gaap:BuildingMember 2025-07-31 0000072331 us-gaap:BuildingMember 2024-10-31 0000072331 us-gaap:MachineryAndEquipmentMember 2025-07-31 0000072331 us-gaap:MachineryAndEquipmentMember 2024-10-31 0000072331 ndsn:EnterpriseManagementSystemsMember 2025-07-31 0000072331 ndsn:EnterpriseManagementSystemsMember 2024-10-31 0000072331 us-gaap:ConstructionInProgressMember 2025-07-31 0000072331 us-gaap:ConstructionInProgressMember 2024-10-31 0000072331 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2025-07-31 0000072331 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2024-10-31 0000072331 ndsn:IndustrialPrecisionSolutionsMember 2024-10-31 0000072331 ndsn:MedicalFluidSystemsMember 2024-10-31 0000072331 ndsn:AdvancedTechnologySolutionsMember 2024-10-31 0000072331 ndsn:IndustrialPrecisionSolutionsMember 2025-07-31 0000072331 ndsn:MedicalFluidSystemsMember 2025-07-31 0000072331 ndsn:AdvancedTechnologySolutionsMember 2025-07-31 0000072331 ndsn:IndustrialPrecisionSolutionsMember 2024-11-01 2025-07-31 0000072331 ndsn:AdvancedTechnologySolutionsMember 2024-11-01 2025-07-31 0000072331 us-gaap:CustomerRelationshipsMember 2025-07-31 0000072331 us-gaap:PatentedTechnologyMember 2025-07-31 0000072331 us-gaap:TradeNamesMember 2025-07-31 0000072331 us-gaap:NoncompeteAgreementsMember 2025-07-31 0000072331 us-gaap:OtherIntangibleAssetsMember 2025-07-31 0000072331 us-gaap:CustomerRelationshipsMember 2024-10-31 0000072331 us-gaap:PatentedTechnologyMember 2024-10-31 0000072331 us-gaap:TradeNamesMember 2024-10-31 0000072331 us-gaap:NoncompeteAgreementsMember 2024-10-31 0000072331 us-gaap:OtherIntangibleAssetsMember 2024-10-31 0000072331 country:US us-gaap:PensionPlansDefinedBenefitMember 2025-05-01 2025-07-31 0000072331 country:US us-gaap:PensionPlansDefinedBenefitMember 2024-05-01 2024-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2025-05-01 2025-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-05-01 2024-07-31 0000072331 country:US us-gaap:PensionPlansDefinedBenefitMember 2024-11-01 2025-07-31 0000072331 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-11-01 2024-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-11-01 2025-07-31 0000072331 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-11-01 2024-07-31 0000072331 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2025-05-01 2025-07-31 0000072331 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-05-01 2024-07-31 0000072331 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-11-01 2025-07-31 0000072331 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-11-01 2024-07-31 0000072331 us-gaap:AccumulatedTranslationAdjustmentMember 2024-10-31 0000072331 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-10-31 0000072331 us-gaap:AccumulatedTranslationAdjustmentMember 2024-11-01 2025-07-31 0000072331 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-11-01 2025-07-31 0000072331 us-gaap:AccumulatedTranslationAdjustmentMember 2025-07-31 0000072331 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-07-31 0000072331 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-11-01 2025-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2024-11-01 2025-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2025-05-01 2025-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2024-05-01 2024-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2023-11-01 2024-07-31 0000072331 us-gaap:EmployeeStockOptionMember 2024-10-31 0000072331 us-gaap:EmployeeStockOptionMember 2025-07-31 0000072331 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-11-01 2025-07-31 0000072331 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-11-01 2024-07-31 0000072331 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-11-01 2024-07-31 0000072331 srt:MinimumMember ndsn:RestrictedSharesAndRestrictedShareUnitsMember 2024-11-01 2025-07-31 0000072331 srt:MaximumMember ndsn:RestrictedSharesAndRestrictedShareUnitsMember 2024-11-01 2025-07-31 0000072331 us-gaap:RestrictedStockMember 2024-11-01 2025-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2024-10-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2024-11-01 2025-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2025-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2025-05-01 2025-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2024-05-01 2024-07-31 0000072331 us-gaap:RestrictedStockUnitsRSUMember 2023-11-01 2024-07-31 0000072331 us-gaap:PerformanceSharesMember 2024-11-01 2025-07-31 0000072331 us-gaap:PerformanceSharesMember ndsn:GrantDateOneMember 2025-07-31 0000072331 us-gaap:PerformanceSharesMember ndsn:GrantDateOneMember 2024-07-31 0000072331 us-gaap:PerformanceSharesMember ndsn:GrantDateTwoMember 2024-07-31 0000072331 us-gaap:PerformanceSharesMember 2025-05-01 2025-07-31 0000072331 us-gaap:PerformanceSharesMember 2024-05-01 2024-07-31 0000072331 us-gaap:PerformanceSharesMember 2023-11-01 2024-07-31 0000072331 us-gaap:PerformanceSharesMember 2025-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember 2024-11-01 2025-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember 2025-05-01 2025-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember 2024-05-01 2024-07-31 0000072331 ndsn:EmployeeDeferredCompensationPlanMember 2023-11-01 2024-07-31 0000072331 us-gaap:DeferredCompensationShareBasedPaymentsMember srt:DirectorMember 2024-10-31 0000072331 us-gaap:DeferredCompensationShareBasedPaymentsMember srt:DirectorMember 2025-05-01 2025-07-31 0000072331 us-gaap:DeferredCompensationShareBasedPaymentsMember srt:DirectorMember 2024-11-01 2025-07-31 0000072331 us-gaap:DeferredCompensationShareBasedPaymentsMember srt:DirectorMember 2025-07-31 0000072331 srt:DirectorMember ndsn:EmployeeDeferredCompensationPlanMember 2025-05-01 2025-07-31 0000072331 srt:DirectorMember ndsn:EmployeeDeferredCompensationPlanMember 2024-05-01 2024-07-31 0000072331 srt:DirectorMember ndsn:EmployeeDeferredCompensationPlanMember 2024-11-01 2025-07-31 0000072331 srt:DirectorMember ndsn:EmployeeDeferredCompensationPlanMember 2023-11-01 2024-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:IndustrialPrecisionSolutionsMember 2025-05-01 2025-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:MedicalAndFluidSolutionsMember 2025-05-01 2025-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:AdvancedTechnologySolutionsMember 2025-05-01 2025-07-31 0000072331 us-gaap:CorporateNonSegmentMember 2025-05-01 2025-07-31 0000072331 us-gaap:OperatingSegmentsMember 2025-05-01 2025-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:IndustrialPrecisionSolutionsMember 2024-05-01 2024-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:MedicalAndFluidSolutionsMember 2024-05-01 2024-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:AdvancedTechnologySolutionsMember 2024-05-01 2024-07-31 0000072331 us-gaap:CorporateNonSegmentMember 2024-05-01 2024-07-31 0000072331 us-gaap:OperatingSegmentsMember 2024-05-01 2024-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:IndustrialPrecisionSolutionsMember 2024-11-01 2025-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:MedicalAndFluidSolutionsMember 2024-11-01 2025-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:AdvancedTechnologySolutionsMember 2024-11-01 2025-07-31 0000072331 us-gaap:CorporateNonSegmentMember 2024-11-01 2025-07-31 0000072331 us-gaap:OperatingSegmentsMember 2024-11-01 2025-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:IndustrialPrecisionSolutionsMember 2023-11-01 2024-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:MedicalAndFluidSolutionsMember 2023-11-01 2024-07-31 0000072331 us-gaap:OperatingSegmentsMember ndsn:AdvancedTechnologySolutionsMember 2023-11-01 2024-07-31 0000072331 us-gaap:CorporateNonSegmentMember 2023-11-01 2024-07-31 0000072331 us-gaap:OperatingSegmentsMember 2023-11-01 2024-07-31 0000072331 ndsn:AmericasExcludingUnitedStatesMember 2025-05-01 2025-07-31 0000072331 ndsn:AmericasExcludingUnitedStatesMember 2024-05-01 2024-07-31 0000072331 ndsn:AmericasExcludingUnitedStatesMember 2024-11-01 2025-07-31 0000072331 ndsn:AmericasExcludingUnitedStatesMember 2023-11-01 2024-07-31 0000072331 srt:EuropeMember 2025-05-01 2025-07-31 0000072331 srt:EuropeMember 2024-05-01 2024-07-31 0000072331 srt:EuropeMember 2024-11-01 2025-07-31 0000072331 srt:EuropeMember 2023-11-01 2024-07-31 0000072331 ndsn:AsiaPacificExcludingJapanMember 2025-05-01 2025-07-31 0000072331 ndsn:AsiaPacificExcludingJapanMember 2024-05-01 2024-07-31 0000072331 ndsn:AsiaPacificExcludingJapanMember 2024-11-01 2025-07-31 0000072331 ndsn:AsiaPacificExcludingJapanMember 2023-11-01 2024-07-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember 2025-07-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-07-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-07-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-07-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember 2024-10-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-10-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-10-31 0000072331 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-10-31 0000072331 us-gaap:ForeignExchangeContractMember currency:EUR us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:EUR us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:GBP us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:GBP us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:JPY us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:JPY us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:MXN us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:MXN us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:HKD us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:HKD us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:SGD us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:SGD us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:AUD us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:AUD us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:TWD us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:TWD us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember srt:OtherCurrencyMember us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember srt:OtherCurrencyMember us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2025-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:EUR us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:EUR us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:GBP us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:GBP us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:MXN us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:MXN us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:JPY us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:JPY us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:HKD us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:HKD us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:SGD us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:SGD us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:AUD us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:AUD us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:TWD us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember currency:TWD us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember srt:OtherCurrencyMember us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember srt:OtherCurrencyMember us-gaap:LongMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2024-07-31 0000072331 us-gaap:ForeignExchangeContractMember us-gaap:LongMember 2024-07-31 0000072331 ndsn:Due2029Member 2024-09-04 2024-09-04 0000072331 ndsn:Due2029Member 2024-09-09 0000072331 ndsn:Due2029Member 2024-09-04 0000072331 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2025-07-31 0000072331 us-gaap:OtherAssetsMember 2025-07-31 0000072331 us-gaap:AccruedLiabilitiesMember 2025-07-31 0000072331 us-gaap:OtherNoncurrentLiabilitiesMember 2025-07-31 0000072331 ndsn:RevolvingCreditAgreementDue2028Member 2025-07-31 0000072331 ndsn:RevolvingCreditAgreementDue2028Member 2024-10-31 0000072331 ndsn:TermLoanDue2026Member 2025-07-31 0000072331 ndsn:TermLoanDue2026Member 2024-10-31 0000072331 ndsn:SeniorNotesDue20232025Member 2025-07-31 0000072331 ndsn:SeniorNotesDue20232025Member 2024-10-31 0000072331 ndsn:SeniorNotesDue20232027Member 2025-07-31 0000072331 ndsn:SeniorNotesDue20232027Member 2024-10-31 0000072331 ndsn:SeniorNotesDue20232030Member 2025-07-31 0000072331 ndsn:SeniorNotesDue20232030Member 2024-10-31 0000072331 ndsn:Due2028Member 2023-09-13 0000072331 ndsn:Due2028Member 2024-10-31 0000072331 ndsn:Due2033Member 2023-09-13 0000072331 ndsn:Due2033Member 2024-10-31 0000072331 ndsn:Due2029Member 2024-10-31 0000072331 2023-06-06 0000072331 ndsn:TermLoanDue2026Member 2023-06-06 0000072331 ndsn:RevolvingCreditAgreementDue2028Member 2023-06-06 0000072331 ndsn:RevolvingCreditAgreementDue2028Member srt:MinimumMember 2023-06-06 0000072331 ndsn:RevolvingCreditAgreementDue2028Member srt:MaximumMember 2023-06-06 0000072331 us-gaap:RevolvingCreditFacilityMember 2025-07-31 0000072331 ndsn:SeniorNotesDue20232027Member 2024-11-01 2025-07-31 0000072331 ndsn:SeniorNotesDue20232030Member 2024-11-01 2025-07-31 0000072331 ndsn:StephenP.LovassMember 2025-05-01 2025-07-31 0000072331 ndsn:StephenP.LovassMember 2025-07-31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2025
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission file number 0-7977
____________________________________________________
NORDSON CORPORATION
(Exact name of registrant as specified in its charter)
___________________________________________________
Ohio
(State or other jurisdiction of incorporation or organization)
28601 Clemens Road
Westlake, Ohio
(Address of principal executive offices)
34-0590250
(I.R.S. Employer Identification No.)
44145
(Zip Code)
(440) 892-1580
(Registrant's Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class |  | Trading Symbol(s) |  | Name of Each Exchange On Which Registered
Common Shares, without par value |  | NDSN |  | Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes x No o
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: Common Shares, without par value as of August 18, 2025: 56,186,303

Table of Contents

PART I – FINANCIAL INFORMATION | 3
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) | 3
Condensed Consolidated Statements of Income | 3
Consolidated Statements of Comprehensive Income | 3
Consolidated Balance Sheets | 4
Consolidated Statements of Shareholders' Equity | 5
Condensed Consolidated Statements of Cash Flows | 7
Notes to Condensed Consolidated Financial Statements | 8
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 23
Overview | 23
Critical Accounting Policies and Estimates | 23
Results of Operations | 24
Financial Condition | 28
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 29
ITEM 4. CONTROLS AND PROCEDURES | 29
PART II – OTHER INFORMATION | 30
ITEM 1. LEGAL PROCEEDINGS | 30
ITEM 1A. RISK FACTORS | 30
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 30
ITEM 5. OTHER INFORMATION | 31
ITEM 6. EXHIBITS | 31
SIGNATURE | 31

Page 2

Table of Contents
Nordson Corporation
Part I – FINANCIAL INFORMATION

ITEM 1. | FINANCIAL STATEMENTS (UNAUDITED)

Condensed Consolidated Statements of Income

|  | Three Months Ended |  | Nine Months Ended
(In thousands, except for per share data) |  | July 31, 2025 |  | July 31, 2024 |  | July 31, 2025 |  | July 31, 2024
Sales |  | $ | 741,509 |  |  | $ | 661,604 |  |  | $ | 2,039,867 |  |  | $ | 1,945,439 |
Operating costs and expenses: |  |  |  |  |  |  |  |
Cost of sales |  | 334,992 |  |  | 292,603 |  |  | 923,550 |  |  | 862,134 |
Selling and administrative expenses |  | 206,539 |  |  | 201,943 |  |  | 606,642 |  |  | 588,196 |
Divestiture and related charges |  | 12,211 |  |  | — |  |  | 12,211 |  |  | — |
|  | 553,742 |  |  | 494,546 |  |  | 1,542,403 |  |  | 1,450,330 |
Operating profit |  | 187,767 |  |  | 167,058 |  |  | 497,464 |  |  | 495,109 |
Other income (expense): |  |  |  |  |  |  |  |
Interest expense |  | (26,258) |  |  | (18,803) |  |  | (79,389) |  |  | (60,354) |
Interest and investment income |  | 560 |  |  | 1,027 |  |  | 2,054 |  |  | 3,625 |
Other - net |  | (2,945) |  |  | 152 |  |  | (5,380) |  |  | (971) |
|  | (28,643) |  |  | (17,624) |  |  | (82,715) |  |  | (57,700) |
Income before income taxes |  | 159,124 |  |  | 149,434 |  |  | 414,749 |  |  | 437,409 |
Income taxes |  | 33,340 |  |  | 32,107 |  |  | 81,909 |  |  | 92,293 |
Net income |  | $ | 125,784 |  |  | $ | 117,327 |  |  | $ | 332,840 |  |  | $ | 345,116 |
Average common shares |  | 56,438 |  |  | 57,229 |  |  | 56,784 |  |  | 57,171 |
Incremental common shares attributable to equity compensation |  | 290 |  |  | 395 |  |  | 300 |  |  | 449 |
Average common shares and common share equivalents |  | 56,728 |  |  | 57,624 |  |  | 57,084 |  |  | 57,620 |
Basic earnings per share |  | $ | 2.23 |  |  | $ | 2.05 |  |  | $ | 5.86 |  |  | $ | 6.04 |
Diluted earnings per share |  | $ | 2.22 |  |  | $ | 2.04 |  |  | $ | 5.83 |  |  | $ | 5.99 |

See accompanying notes.
Consolidated Statements of Comprehensive Income

|  | Three Months Ended |  | Nine Months Ended
(In thousands) |  | July 31, 2025 |  | July 31, 2024 |  | July 31, 2025 |  | July 31, 2024
Net income |  | $ | 125,784 |  |  | $ | 117,327 |  |  | $ | 332,840 |  |  | $ | 345,116 |
Components of other comprehensive income (loss): |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | 4,973 |  |  | 8,096 |  |  | 48,899 |  |  | 19,419 |
Pension and other postretirement plan adjustments, net of tax |  | 290 |  |  | (1,198) |  |  | 382 |  |  | (1,638) |
Total other comprehensive income |  | 5,263 |  |  | 6,898 |  |  | 49,281 |  |  | 17,781 |
Total comprehensive income |  | $ | 131,047 |  |  | $ | 124,225 |  |  | $ | 382,121 |  |  | $ | 362,897 |

See accompanying notes.
Page 3

Table of Contents
Nordson Corporation
Consolidated Balance Sheets

(In thousands) |  |  |  |
Assets |  |  |  |
Current assets: |  | July 31, 2025 |  | October 31, 2024
Cash and cash equivalents |  | $ | 147,788 |  |  | $ | 115,952 |
Receivables - net |  | 588,951 |  |  | 594,663 |
Inventories - net |  | 459,251 |  |  | 476,935 |
Prepaid expenses and other current assets |  | 91,275 |  |  | 87,482 |
Assets held for sale |  | 39,583 |  |  | — |
Total current assets |  | 1,326,848 |  |  | 1,275,032 |
Goodwill |  | 3,306,432 |  |  | 3,280,819 |
Intangible assets - net |  | 698,000 |  |  | 740,846 |
Property, plant and equipment - net |  | 525,604 |  |  | 544,607 |
Operating right of use lease assets |  | 79,770 |  |  | 93,620 |
Deferred income taxes |  | 12,137 |  |  | 11,196 |
Other assets |  | 60,922 |  |  | 54,846 |
Total assets |  | $ | 6,009,713 |  |  | $ | 6,000,966 |
Liabilities and shareholders' equity |  |  |  |
Current liabilities: |  |  |  |
Current maturities of long-term debt and notes payable |  | $ | 336,078 |  |  | $ | 103,928 |
Accrued liabilities |  | 221,335 |  |  | 225,231 |
Accounts payable |  | 129,515 |  |  | 97,839 |
Customer advanced payments |  | 54,966 |  |  | 46,400 |
Income taxes payable |  | 7,236 |  |  | 32,754 |
Operating lease liability - current |  | 17,363 |  |  | 17,063 |
Finance lease liability - current |  | 5,808 |  |  | 5,262 |
Liabilities held for sale |  | 10,807 |  |  | — |
Total current liabilities |  | 783,108 |  |  | 528,477 |
Long-term debt |  | 1,785,745 |  |  | 2,101,197 |
Operating lease liability - noncurrent |  | 67,675 |  |  | 80,818 |
Deferred income taxes |  | 199,146 |  |  | 205,687 |
Postretirement obligations |  | 50,940 |  |  | 51,544 |
Pension obligations |  | 49,783 |  |  | 46,893 |
Finance lease liability - noncurrent |  | 8,226 |  |  | 12,083 |
Other long-term liabilities |  | 83,305 |  |  | 42,075 |
Shareholders' equity: |  |  |  |
Common shares |  | 12,253 |  |  | 12,253 |
Capital in excess of stated value |  | 731,915 |  |  | 714,091 |
Retained earnings |  | 4,495,031 |  |  | 4,295,199 |
Accumulated other comprehensive loss |  | (135,559) |  |  | (184,840) |
Common shares in treasury, at cost |  | (2,121,855) |  |  | (1,904,511) |
Total shareholders' equity |  | 2,981,785 |  |  | 2,932,192 |
Total liabilities and shareholders' equity |  | $ | 6,009,713 |  |  | $ | 6,000,966 |

See accompanying notes.
Page 4

Table of Contents
Nordson Corporation
Consolidated Statements of Shareholders’ Equity

|  | Nine Months Ended July 31, 2025
(In thousands, except for share and per share data) |  | Common Shares |  | Additional Paid-in Capital |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Common Shares in Treasury, at cost |  | TOTAL
November 1, 2024 |  | $ | 12,253 |  |  | $ | 714,091 |  |  | $ | 4,295,199 |  |  | $ | (184,840) |  |  | $ | (1,904,511) |  |  | $ | 2,932,192 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 349 |  |  | — |  |  | — |  |  | 652 |  |  | 1,001 |
Stock-based compensation |  | — |  |  | 4,633 |  |  | — |  |  | — |  |  | — |  |  | 4,633 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (60,098) |  |  | (60,098) |
Dividends declared ($0.78 per share) |  | — |  |  | — |  |  | (44,602) |  |  | — |  |  | — |  |  | (44,602) |
Net income |  | — |  |  | — |  |  | 94,652 |  |  | — |  |  | — |  |  | 94,652 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | (51,679) |  |  | — |  |  | (51,679) |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | 512 |  |  | — |  |  | 512 |
January 31, 2025 |  | $ | 12,253 |  |  | $ | 719,073 |  |  | $ | 4,345,249 |  |  | $ | (236,007) |  |  | $ | (1,963,957) |  |  | $ | 2,876,611 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 1,554 |  |  | — |  |  | — |  |  | 248 |  |  | 1,802 |
Stock-based compensation |  | — |  |  | 4,791 |  |  | — |  |  | — |  |  | — |  |  | 4,791 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (86,154) |  |  | (86,154) |
Dividends declared ($0.78 per share) |  | — |  |  | — |  |  | (44,335) |  |  | — |  |  | — |  |  | (44,335) |
Net income |  | — |  |  | — |  |  | 112,404 |  |  | — |  |  | — |  |  | 112,404 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | 95,605 |  |  | — |  |  | 95,605 |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | (420) |  |  | — |  |  | (420) |
April 30, 2025 |  | $ | 12,253 |  |  | $ | 725,418 |  |  | $ | 4,413,318 |  |  | $ | (140,822) |  |  | $ | (2,049,863) |  |  | $ | 2,960,304 |
Shares issued (repurchased) under company stock and employee benefit plans |  | — |  |  | 2,666 |  |  | — |  |  | — |  |  | (50) |  |  | 2,616 |
Stock-based compensation |  | — |  |  | 3,831 |  |  | — |  |  | — |  |  | — |  |  | 3,831 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (71,942) |  |  | (71,942) |
Dividends declared ($0.78 per share) |  | — |  |  | — |  |  | (44,071) |  |  | — |  |  | — |  |  | (44,071) |
Net income |  | — |  |  | — |  |  | 125,784 |  |  | — |  |  | — |  |  | 125,784 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | 4,973 |  |  | — |  |  | 4,973 |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | 290 |  |  | — |  |  | 290 |
July 31, 2025 |  | $ | 12,253 |  |  | $ | 731,915 |  |  | $ | 4,495,031 |  |  | $ | (135,559) |  |  | $ | (2,121,855) |  |  | $ | 2,981,785 |

Page 5

Table of Contents
Nordson Corporation

|  | Nine Months Ended July 31, 2024
(In thousands, except for share and per share data) |  | Common Shares |  | Additional Paid-in Capital |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Common Shares in Treasury, at cost |  | TOTAL
November 1, 2023 |  | $ | 12,253 |  |  | $ | 668,097 |  |  | $ | 3,989,353 |  |  | $ | (196,441) |  |  | $ | (1,875,202) |  |  | $ | 2,598,060 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 12,519 |  |  | — |  |  | — |  |  | 1,899 |  |  | 14,418 |
Stock-based compensation |  | — |  |  | 4,659 |  |  | — |  |  | — |  |  | — |  |  | 4,659 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (7,371) |  |  | (7,371) |
Dividends declared ($0.68 per share) |  | — |  |  | — |  |  | (38,855) |  |  | — |  |  | — |  |  | (38,855) |
Net income |  | — |  |  | — |  |  | 109,572 |  |  | — |  |  | — |  |  | 109,572 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | 43,943 |  |  | — |  |  | 43,943 |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | (459) |  |  | — |  |  | (459) |
January 31, 2024 |  | $ | 12,253 |  |  | $ | 685,275 |  |  | $ | 4,060,070 |  |  | $ | (152,957) |  |  | $ | (1,880,674) |  |  | $ | 2,723,967 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 11,412 |  |  | — |  |  | — |  |  | 1,389 |  |  | 12,801 |
Stock-based compensation |  | — |  |  | 5,384 |  |  | — |  |  | — |  |  | — |  |  | 5,384 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (556) |  |  | (556) |
Dividends declared ($0.68 per share) |  | — |  |  | — |  |  | (38,941) |  |  | — |  |  | — |  |  | (38,941) |
Net income |  | — |  |  | — |  |  | 118,217 |  |  | — |  |  | — |  |  | 118,217 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | (32,620) |  |  | — |  |  | (32,620) |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | 19 |  |  | — |  |  | 19 |
April 30, 2024 |  | $ | 12,253 |  |  | $ | 702,071 |  |  | $ | 4,139,346 |  |  | $ | (185,558) |  |  | $ | (1,879,841) |  |  | $ | 2,788,271 |
Shares issued under company stock and employee benefit plans |  | — |  |  | 1,490 |  |  | — |  |  | — |  |  | 433 |  |  | 1,923 |
Stock-based compensation |  | — |  |  | 4,509 |  |  | — |  |  | — |  |  | — |  |  | 4,509 |
Purchase of treasury shares |  | — |  |  | — |  |  | — |  |  | — |  |  | (26,178) |  |  | (26,178) |
Dividends declared ($0.68 per share) |  | — |  |  | — |  |  | (38,993) |  |  | — |  |  | — |  |  | (38,993) |
Net income |  | — |  |  | — |  |  | 117,327 |  |  | — |  |  | — |  |  | 117,327 |
Other Comprehensive Income (Loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  | — |  |  | — |  |  | — |  |  | 8,096 |  |  | — |  |  | 8,096 |
Defined benefit pension and post-retirement plan adjustments |  | — |  |  | — |  |  | — |  |  | (1,198) |  |  | — |  |  | (1,198) |
July 31, 2024 |  | $ | 12,253 |  |  | $ | 708,070 |  |  | $ | 4,217,680 |  |  | $ | (178,660) |  |  | $ | (1,905,586) |  |  | $ | 2,853,757 |

See accompanying notes.
Page 6

Table of Contents
Nordson Corporation
Condensed Consolidated Statements of Cash Flows

(In thousands) |  | Nine Months Ended
Cash flows from operating activities: |  | July 31, 2025 |  | July 31, 2024
Net income |  | $ | 332,840 |  |  | $ | 345,116 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |
Depreciation and amortization |  | 112,454 |  |  | 99,646 |
Non-cash stock compensation |  | 13,255 |  |  | 14,552 |
Deferred income taxes |  | (3,303) |  |  | (3,830) |
Other non-cash expense |  | 2,009 |  |  | 3,698 |
Loss on sale of property, plant and equipment |  | 193 |  |  | 1,015 |
Divestiture and related charges |  | 12,211 |  |  | — |
Changes in operating assets and liabilities and other |  | 46,605 |  |  | (385) |
Net cash provided by operating activities |  | 516,264 |  |  | 459,812 |
Cash flows from investing activities: |  |  |  |
Additions to property, plant and equipment |  | (49,002) |  |  | (43,786) |
Proceeds from sale of property, plant and equipment |  | 305 |  |  | 63 |
Other |  | 3,967 |  |  | 8,833 |
Net cash used in investing activities |  | (44,730) |  |  | (34,890) |
Cash flows from financing activities: |  |  |  |
Proceeds from issuance of debt |  | 24,952 |  |  | 4,334 |
Repayment of debt |  | (119,616) |  |  | (248,689) |
Repayment of finance lease obligations |  | (4,083) |  |  | (4,505) |
Issuance of common shares in treasury |  | 5,419 |  |  | 29,142 |
Purchase of treasury shares |  | (218,194) |  |  | (34,105) |
Dividends paid |  | (133,008) |  |  | (116,789) |
Net cash used in financing activities |  | (444,530) |  |  | (370,612) |
Effect of exchange rate changes on cash |  | 4,832 |  |  | (4,665) |
Increase in cash and cash equivalents |  | 31,836 |  |  | 49,645 |
Cash and cash equivalents at beginning of period |  | 115,952 |  |  | 115,679 |
Cash and cash equivalents at end of period |  | $ | 147,788 |  |  | $ | 165,324 |

See accompanying notes.
Page 7

Table of Contents
Nordson Corporation
Notes to Condensed Consolidated Financial Statements
July 31, 2025
NOTE REGARDING AMOUNTS AND FISCAL YEAR REFERENCES
In this Quarterly Report on Form 10-Q, all amounts related to United States dollars and foreign currency and to the number of Nordson Corporation’s common shares, except for per share earnings and dividend amounts, are expressed in thousands. Unless the context otherwise indicates, all references to “we” or the “Company” mean Nordson Corporation.
Unless otherwise noted, all references to years relate to our fiscal year ending October 31.
Significant accounting policies
Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States ("U.S. GAAP") for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended July 31, 2025 are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the Consolidated Financial Statements and notes included in our Annual Report on Form 10-K for the year ended October 31, 2024.
Consolidation. The Condensed Consolidated Financial Statements include the accounts of Nordson Corporation and its 100%-owned and controlled subsidiaries. Investments in affiliates and joint ventures in which our ownership is 50% or less or in which we do not have control but have the ability to exercise significant influence are accounted for under the equity method. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates. The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements. Actual amounts could differ from these estimates.
Revenue recognition. A contract exists when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied. Generally, our revenue results from short-term, fixed-price contracts and primarily is recognized as of a point in time when the product is shipped or at a later point when the control of the product transfers to the customer. For products in which control transfers upon delivery, revenue is deferred for undelivered items and included within Accrued liabilities in our Consolidated Balance Sheets. Revenues deferred as of July 31, 2025 and October 31, 2024 were not material. For certain contracts, the Company may collect payments in advance of completing performance obligations and recognizes a liability included within Customer advance payments in our Consolidated Balance Sheets.
However, for certain contracts related to the sale of customer-specific products within our Medical and Fluid Solutions ("MFS") segment, revenue is recognized over time as we satisfy performance obligations because of the continuous transfer of control to the customer. The continuous transfer of control to the customer occurs as we enhance assets that are customer controlled, and we are contractually entitled to payment for work performed to date plus a reasonable margin.
As control transfers over time for these products or services, revenue is recognized based on progress toward completion of the performance obligations. The selection method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. We have elected to use the input method – costs incurred for these contracts because it best depicts the transfer of products or services to the customer based on incurring costs on the contract. Under this method, revenues are recorded proportionally as costs are incurred. Contract assets recognized are recorded in Prepaid expenses and other current assets and contract liabilities are recorded in Accrued liabilities in our Consolidated Balance Sheets and were not material as of July 31, 2025 and October 31, 2024. Revenue recognized over time represented approximately less than ten percent of our overall consolidated revenues for the year-to-date periods ended July 31, 2025 and October 31, 2024.
Revenue is measured as the amount of consideration we expect to be entitled to in exchange for transferring products or services. Taxes, including sales and value add, that we collect concurrently with revenue-producing activities are excluded from revenue. As a practical expedient, we may exclude the assessment of whether goods or services are performance obligations, if they are immaterial in the context of the contract, and combine these with other performance obligations. While payment terms and conditions vary by contract type, we have determined that our contracts generally do not include a significant financing component. We have elected to apply the practical expedient to treat all shipping and handling costs as fulfillment costs, as a
Page 8

Table of Contents
Nordson Corporation
significant portion of these costs are incurred prior to transfer of control to the customer. We have also elected to apply the practical expedient to expense sales commissions as they are incurred, as the amortization period resulting from capitalizing the costs is one year or less. These costs are recorded within Selling and administrative expenses in our Condensed Consolidated Statements of Income.
We offer assurance-type warranties on our products as well as separately sold warranty contracts. Revenue related to warranty contracts that are sold separately is recognized over the life of the warranty term and is not material. Certain arrangements may include installation, installation supervision, training, and spare parts, which tend to be completed in a short period of time, at an insignificant cost, and utilizing skills not unique to us, and therefore, these items are typically regarded as inconsequential or not material.
We disclose disaggregated revenues by operating segment and geography in accordance with the revenue standard and on the same basis used internally by the chief operating decision maker for evaluating performance of operating segments and for allocating resources. Refer to our Operating segments Note for details.
Earnings per share. Basic earnings per share are computed based on the weighted-average number of common shares outstanding during each year, while diluted earnings per share are based on the weighted-average number of common shares and common share equivalents outstanding. Common share equivalents consist of shares issuable upon exercise of stock options computed using the treasury stock method, as well as restricted shares and deferred stock-based compensation. Options whose exercise price is higher than the average market price are excluded from the calculation of diluted earnings per share because the effect would be anti-dilutive. Options excluded from the calculation of diluted earnings per share for the three months ended July 31, 2025 and 2024 were 190 and 74, respectively. Options excluded from the calculation of diluted earnings per share for the nine months ended July 31, 2025 and 2024 were 240 and 74, re spectively.
Recently issued accounting standards
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company plans to adopt this standard beginning with our Annual Report on Form 10-K for the fiscal year ending October 31, 2025. While we expect the adoption of this standard will expand our disclosures related to our operating segments, we do not expect it to have any impact on our consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring specific disclosure in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures and anticipates adoption in fiscal 2026.
In November 2024, the FASB issued ASU 2024-03, Income Statement (Topic 220): Reporting Comprehensive Income. ASU 2024-03 does not change or remove current expense presentation requirements within the Condensed Consolidated Statements of Income. However, the amendments require disclosure, on an annual and interim basis, disaggregated information about certain income statement expense line items within the notes to the consolidated financial statements. The ASU requires entities to disaggregate any relevant expense caption presented on the face of the income statement within continuing operations into expense categories such as: purchases of inventory, employee compensation, depreciation and intangible asset amortization. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures and anticipates adoption in fiscal 2028.
Acquisitions
Business acquisitions have been accounted for using the acquisition method, with the acquired assets and liabilities recorded at estimated fair value on the dates of acquisition. The cost in excess of the net assets of the business acquired is included in goodwill. Operating results since the respective dates of acquisitions are included in the Condensed Consolidated Statements of Income.
2024 Acquisition
On August 21, 2024, the Company completed the acquisition of Atrion Corporation, a Delaware corporation (“Atrion”), pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated May 28, 2024, with Alpha Medical Merger
Page 9

Table of Contents
Nordson Corporation
Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Nordson (“Merger Sub”), and Atrion. Pursuant to the Merger Agreement, Merger Sub merged with and into Atrion (the “Merger”), with Atrion surviving the Merger as a wholly owned subsidiary of Nordson. Atrion is a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions and operates within our MFS segment. The all-cash acquisition of Atrion of $789,996, net of cash acquired, was funded using borrowings under our revolving credit facility and the 364-day term loan agreement with a group of banks for a delayed draw term loan facility in the aggregate principal amount of $500,000 (the “364-Day Term Loan Agreement”) and cash on hand. Based on the fair value of the assets acquired and the liabilities assumed, a preliminary purchase price allocation resulted in the recognition of $494,279 of goodwill and $129,600 of identifiable intangible assets. The identifiable intangible assets consist primarily of $40,100 of tradenames (amortized over 15 years), $24,900 of technology (amortized over 15 years), and $64,600 of customer relationships (amortized over 19 years). Goodwill associated with the acquisition was not tax deductible. As of July 31, 2025, the purchase price allocation remains preliminary as we complete our assessment, principally related to income taxes. The financial results of the Atrion acquisition are not expected to have a material impact on our Consolidated Financial Statements.
The assets and liabilities acquired were as follows:

| August 21, 2024
Cash | $ | 24,428 |
Receivables - net | 20,883 |
Inventories - net | 64,801 |
Goodwill | 494,279 |
Intangibles | 129,600 |
Other assets | 157,473 |
Total Assets | $ | 891,464 |
Accounts payable | $ | 25,587 |
Deferred income taxes | 31,221 |
Other liabilities | 20,232 |
Total Liabilities | $ | 77,040 |

Divestiture and related charges
In the third quarter of 2025, we entered into a definitive agreement to sell select product lines in the medical contract manufacturing business within the MFS segment and determined that the criteria to be classified as held for sale were met. Therefore, these assets and liabilities have been presented as held for sale in the Consolidated Balance Sheet as of July 31, 2025. Assets and liabilities classified as held for sale are measured at the lower of carrying value or fair value less costs to sell.
Before measuring the fair value less costs to sell of the disposal group as a whole, we first reviewed individual assets and liabilities to determine if any fair value adjustments were required and concluded no individual asset impairments were required. Then, based on the definitive agreement entered into by us and the buyer, we determined the fair value of the disposal group to be equal to the selling price, less costs to sell. Based on this review, we recorded a non-cash impairment charge of $4,726.
Page 10

Table of Contents
Nordson Corporation
The assets and liabilities of the disposal group classified as held for sale at July 31, 2025 were as follows:

| July 31, 2025 |  |
Receivables - net | $ | 4,650 |  |  |
Inventories - net | 5,602 |  |  |
Prepaid expenses and other current assets | 5,877 |  |  |
Property, plant and equipment - net | 13,988 |  |  |
Operating right of use lease assets | 3,627 |  |  |
Goodwill | 10,565 |  |  |
Impairment on carrying value | (4,726) |  |  |
Assets held for sale | $ | 39,583 |  |  |
Accounts payable | $ | 703 |  |  |
Accrued liabilities | 1,729 |  |  |
Operating lease liability | 3,685 |  |  |
Finance lease liability | 4,690 |  |  |
Liabilities held for sale | $ | 10,807 |  |  |

The pending sale of select product lines in the medical contract manufacturing business is subject to customary closing conditions and is expected to close no later than the fourth quarter of 2025.
In the third quarter of 2025, as part of its exit of the medical contract manufacturing business, the Company also announced the planned closure of its remaining medical contract manufacturing facility and recognized a charge of $7,485, principally associated with the write-off of leasehold improvements and the write-down of an operating right of use lease asset.
Excluding the non-cash divestiture and related charges of $12,211 recorded in the third quarter of 2025, the operating results of the medical contract manufacturing business were not material to our Consolidated Financial Statements for any period presented.
Receivables
Our allowance for credit losses is principally determined based on aging of receivables. Receivables are exposed to credit risk based on the customers' ability to pay which is influenced by, among other factors, their financial liquidity. We perform ongoing customer credit evaluation to maintain sufficient allowances for potential credit losses. Our segments perform credit evaluation and monitoring to estimate and manage credit risk through the review of customer information, credit ratings, approval and monitoring of customer credit limits, and assessment of market conditions. We may also require prepayments or bank guarantees from customers to mitigate credit risk. Our receivables are generally short-term in nature with a majority of receivables outstanding less than 90 days. Accounts receivable balances are written-off against the allowance if deemed uncollectible.
Accounts receivable are net of an allowance for credit losses of $6,908 a nd $9,769 o n July 31, 2025 and October 31, 2024, respectively. P rovision income was $161 and $805 for the three and nine months ended July 31, 2025, respectively, co mpared to provision expense of $1,678 and $2,156 for the same periods a year ago, respectively. The remaining change in the allowance for credit losses is principally related to net write-off/recoveries of uncollectible accounts as well as currency translation.
Page 11

Table of Contents
Nordson Corporation
Inventories
Components of inventories were as follows:

|  | July 31, 2025 |  | October 31, 2024
Finished goods |  | $ | 250,681 |  |  | $ | 256,465 |
Raw materials and component parts |  | 229,547 |  |  | 250,477 |
Work-in-process |  | 64,552 |  |  | 55,790 |
|  | 544,780 |  |  | 562,732 |
Obsolescence and other reserves |  | (85,529) |  |  | (85,797) |
|  | $ | 459,251 |  |  | $ | 476,935 |

Property, Plant and Equipment
Components of property, plant and equipment were as follows:

| July 31, 2025 |  | October 31, 2024
Land | $ | 32,517 |  |  | $ | 32,018 |
Land improvements | 4,841 |  |  | 4,822 |
Buildings | 360,881 |  |  | 354,854 |
Machinery and equipment | 674,321 |  |  | 649,510 |
Enterprise management system | 53,678 |  |  | 53,401 |
Construction-in-progress | 36,060 |  |  | 58,362 |
Leased property under finance leases | 26,727 |  |  | 29,404 |
| 1,189,025 |  |  | 1,182,371 |
Accumulated depreciation and amortization | (663,421) |  |  | (637,764) |
| $ | 525,604 |  |  | $ | 544,607 |

Depreciation expense was $17,754 and $14,180 for the three months ended July 31, 2025 and 2024, respectively. Depreciation expense was $53,355 and $42,234 for the nine months ended July 31, 2025 and 2024, respectively.
Goodwill and other intangible assets
Changes in the carrying amount of goodwill for th e nine months ended July 31, 2025 by operating segment were as follows:

|  | Industrial Precision Solutions |  | Medical and Fluid Solutions |  | Advanced Technology Solutions |  | Total
Balance at October 31, 2024 |  | $ | 1,207,631 |  |  | $ | 1,669,748 |  |  | $ | 403,440 |  |  | $ | 3,280,819 |
Other |  | — |  |  | (10,565) |  |  | — |  |  | (10,565) |
Division transfer |  | (29,010) |  |  | — |  |  | 29,010 |  |  | — |
Currency effect |  | 20,290 |  |  | 1,967 |  |  | 13,921 |  |  | 36,178 |
Balance at July 31, 2025 |  | $ | 1,198,911 |  |  | $ | 1,661,150 |  |  | $ | 446,371 |  |  | $ | 3,306,432 |

The Other activity above reflects an allocation of goodwill to the disposal group classified as held for sale. See Divestiture and related charges note.
Effective November 1, 2024, the Measurement and Control Solutions ("MCS") division was transferred from the Industrial Precision Solutions ("IPS") segment to the Advanced Technology Solutions ("ATS") segment due to an organizational change and determination that the economic and business characteristics of MCS better aligned with the Company’s ATS segment. The division transfer above reflects the transfer of goodwill from IPS to ATS as a result of this change.
In the first quarter of 2025, the Company also reassessed its reporting units for purposes of annual goodwill impairment testing due to a number of recent developments, including the status of integration activities associated with several significant acquisitions over the last few years and changes in the management of divisions, such as the transfer of MCS to the ATS segment. As a result of this reassessment and in consideration of the Company's management reporting structure, economic characteristics of the divisions and nature of the products and services of those divisions, the Company determined its reporting units should be
Page 12

Table of Contents
Nordson Corporation
the same as its operating segments: ATS, IPS and MFS. In accordance with ASC 350, Intangibles - Goodwill and Other, the Company properly assessed for indicators of impairment of goodwill at the time of the reporting unit change, concluding that no impairment existed.
Information regarding our intangible assets subject to amortization was as follows:

|  | July 31, 2025
|  | Carrying Amount |  | Accumulated Amortization |  | Net Book Value
Customer relationships |  | $ | 896,298 |  |  | $ | 378,959 |  |  | $ | 517,339 |
Patent/technology costs |  | 234,559 |  |  | 150,307 |  |  | 84,252 |
Trade name |  | 169,036 |  |  | 72,627 |  |  | 96,409 |
Non-compete agreements |  | 8,637 |  |  | 8,637 |  |  | — |
Other |  | 390 |  |  | 390 |  |  | — |
Total |  | $ | 1,308,920 |  |  | $ | 610,920 |  |  | $ | 698,000 |
|  | October 31, 2024
|  | Carrying Amount |  | Accumulated Amortization |  | Net Book Value
Customer relationships |  | $ | 878,071 |  |  | $ | 339,756 |  |  | $ | 538,315 |
Patent/technology costs |  | 232,371 |  |  | 134,187 |  |  | 98,184 |
Trade name |  | 167,144 |  |  | 62,887 |  |  | 104,257 |
Non-compete agreements |  | 8,502 |  |  | 8,412 |  |  | 90 |
Other |  | 500 |  |  | 500 |  |  | — |
Total |  | $ | 1,286,588 |  |  | $ | 545,742 |  |  | $ | 740,846 |

Amortization expense for the three months ended July 31, 2025 and 2024 was $20,092 and $19,202, respectively. Amortization expense for the nine months ended July 31, 2025 and 2024 was $59,099 and $57,412, respectively.
Pension and other postretirement plans
The components of net periodic pension for the three and nine months ended July 31, 2025 and 2024 were:

|  | U.S. |  | International
Three Months Ended |  | 2025 |  | 2024 |  | 2025 |  | 2024
Service cost |  | $ | 2,531 |  |  | $ | 2,507 |  |  | $ | 250 |  |  | $ | 231 |
Interest cost |  | 4,691 |  |  | 4,752 |  |  | 675 |  |  | 688 |
Expected return on plan assets |  | (6,609) |  |  | (6,652) |  |  | (683) |  |  | (417) |
Amortization of prior service credit |  | — |  |  | — |  |  | (2) |  |  | (2) |
Amortization of net actuarial (gain) loss |  | 474 |  |  | — |  |  | (72) |  |  | 7 |
Settlement loss |  | — |  |  | 56 |  |  | — |  |  | — |
Total benefit cost |  | $ | 1,087 |  |  | $ | 663 |  |  | $ | 168 |  |  | $ | 507 |
|  | U.S. |  | International
Nine Months Ended |  | 2025 |  | 2024 |  | 2025 |  | 2024
Service cost |  | $ | 7,592 |  |  | $ | 7,522 |  |  | $ | 721 |  |  | $ | 702 |
Interest cost |  | 14,074 |  |  | 14,257 |  |  | 1,937 |  |  | 2,062 |
Expected return on plan assets |  | (19,827) |  |  | (19,958) |  |  | (1,972) |  |  | (1,250) |
Amortization of prior service credit |  | — |  |  | — |  |  | (6) |  |  | (6) |
Amortization of net actuarial (gain) loss |  | 1,421 |  |  | — |  |  | (208) |  |  | 24 |
Settlement loss |  | — |  |  | 56 |  |  | — |  |  | — |
Total benefit cost |  | $ | 3,260 |  |  | $ | 1,877 |  |  | $ | 472 |  |  | $ | 1,532 |

Page 13

Table of Contents
Nordson Corporation
The components of other postretirement benefit costs, for plans in the United States, for the three and nine months ended July 31, 2025 and 2024:

|  | U.S.
Three Months Ended |  | 2025 |  | 2024
Service cost |  | $ | 59 |  |  | $ | 70 |
Interest cost |  | 657 |  |  | 754 |
Amortization of net actuarial gain |  | (127) |  |  | (147) |
Total benefit cost (income) |  | $ | 589 |  |  | $ | 677 |
|  | U.S.
Nine Months Ended |  | 2025 |  | 2024
Service cost |  | $ | 176 |  |  | $ | 211 |
Interest cost |  | 1,951 |  |  | 2,262 |
Amortization of net actuarial gain |  | (377) |  |  | (443) |
Total benefit cost (income) |  | $ | 1,750 |  |  | $ | 2,030 |

The components of net periodic pension and other postretirement cost, other than service cost, are included in Other – net in our Condensed Consolidated Statements of Income.
Income taxes
We record our interim provision for income taxes based on our estimated annual effective tax rate, as well as certain items discrete to the current period. The effective tax rate for the three months ended July 31, 2025 and 2024 was 21.0% and 21.5%, respectively. The effective tax rate for the nine months ended July 31, 2025 and 2024 was 19.7% and 21.1%, respectively. Excluding a discrete tax impact related to the divestiture and related charges taken in the third quarter of 2025, the effective tax rates for the three and nine months ended July 31, 2025 were 19.4% and 19.2%, respectively. The effective tax rate for the nine months ended July 31, 2025 is lower than the U.S. tax rate of 21% primarily due to the foreign-derived intangible income deduction.
One Big Beautiful Bill Act
On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was signed into law in the U.S. The OBBBA includes significant tax law changes, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The Company is currently evaluating the OBBBA’s impact and does not expect it to have a material impact on its current year consolidated financial statements
Accumulated other comprehensive income (loss)
The components of accumulated other comprehensive income (loss), including adjustments for items that are reclassified from accumulated other comprehensive loss to net income, are shown below.

|  | Cumulative translation adjustments |  | Pension and postretirement benefit plan adjustments |  | Accumulated other comprehensive income (loss)
Balance at October 31, 2024 |  | $ | (116,890) |  |  | $ | (67,950) |  |  | $ | (184,840) |
Pension and other postretirement plan adjustments, net of tax of $99 |  | — |  |  | 382 |  |  | 382 |
Foreign currency translation adjustments (a) |  | 48,899 |  |  | — |  |  | 48,899 |
Balance at July 31, 2025 |  | $ | (67,991) |  |  | $ | (67,568) |  |  | $ | (135,559) |

(a) Includes a net loss of $27,470, net of tax of $8,205, on net investment hedges.
Page 14

Table of Contents
Nordson Corporation
Stock-based compensation
During the 2021 Annual Meeting of Shareholders, our shareholders approved the Nordson Corporation 2021 Stock Incentive and Award Plan (the "2021 Plan") as the successor to the Amended and Restated 2012 Stock Incentive and Award Plan (the "2012 Plan"). The 2021 Plan provides for the granting of stock options, stock appreciation rights, restricted shares, restricted share units, performance shares, cash awards and other stock or performance-based incentives. A maximum of 900 common shares were authorized for grant under the 2021 Plan plus the number of shares that remained available to be granted under the 2012 Plan, as well as issuable under the CyberOptics equity plan. As of July 31, 2025, a total of 2,081 common shares were available to be granted under the 2021 Plan.
Stock Options
Nonqualified or incentive stock options may be granted to our employees and directors. Generally, options granted to employees may be exercised beginning one year from the date of grant at a rate not exceeding 25 percent per year and expire 10 years from the date of grant. Vesting accelerates upon a qualified termination in connection with a change in control. In the event of termination of employment due to early retirement or normal retirement at age 65, options granted within 12 months prior to termination are forfeited, and vesting continues postretirement for all other unvested options granted. In the event of disability or death, all unvested stock options granted within 12 months prior to termination fully vest. Termination for any other reason results in forfeiture of unvested options and vested options in certain circumstances. The amortized cost of options is accelerated if the retirement eligibility date occurs before the normal vesting dat e. Option exercises are satisfied through the issuance of treasury shares on a first-in, first-out basis. We recognized compensation expense related to stock options of $758 and $2,328 for the three and nine months ended July 31, 2025, respectively, compared to $1,426 and $3,960 for the three and nine months ended July 31, 2024, respectively.
The following table summarizes activity related to stock options for the nine months ended July 31, 2025:

|  | Number of Options |  | Weighted- Average Exercise Price Per Share |  | Aggregate Intrinsic Value |  | Weighted Average Remaining Term
Outstanding at October 31, 2024 |  | 855 |  | $ | 167.26 |  |  |  |  |
Granted |  | 60 |  | 209.73 |  |  |  |  |
Exercised |  | (52) |  | 118.73 |  |  |  |  |
Forfeited or expired |  | (10) |  | 224.68 |  |  |  |  |
Outstanding at July 31, 2025 |  | 853 |  | $ | 172.48 |  |  | $ | 42,388 |  |  | 4.4 years
Expected to vest |  | 142 |  | $ | 231.38 |  |  | $ | 256 |  |  | 8.2 years
Exercisable at July 31, 2025 |  | 708 |  | $ | 160.48 |  |  | $ | 42,127 |  |  | 3.6 years

As of July 31, 2025, there was $6,020 of total unrecognized compensation cost related to unvested stock options. That cost is expected to be amortized over a weighted average period of approximately 2.4 years.
The fair value of each option grant was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Nine Months Ended | July 31, 2025 |  | July 31, 2024
Expected volatility | 30.3% | - | 31.2% |  | 30.3% | - | 31.7%
Expected dividend yield | 1.51% | - | 1.51% |  | 1.15% | - | 1.20%
Risk-free interest rate | 4.43% | - | 4.48% |  | 4.22% | - | 4.52%
Expected life of the option (in years) | 5.0 | - | 6.3 |  | 5.0 | - | 6.2

The weighted-average expected volatility used to value the 2025 and 2024 options was 30.5% and 30.7%, respectively.
Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued.
The weighted average grant date fair value of stock options granted during the nine months ended July 31, 2025 and 2024 was $68.11 and $79.84, respectively.
The total intrinsic value of options exercised during the three months ended July 31, 2025 and 2024 was $2,315 and $3,115, respectively. The total intrinsic value of options exercised during the nine months ended July 31, 2025 and 2024 was $4,875 and $33,286, respectively.
Page 15

Table of Contents
Nordson Corporation
Cash received from the exercise of stock options for the nine months ended July 31, 2025 and 2024 was $5,419 and $29,142, respectively.
Restricted Shares and Restricted Share Units
We may grant restricted shares and/or restricted share units to our employees and directors. These shares or units may not be transferred for a designated period of time (generally one to three years) defined at the date of grant. We may also grant continuation awards in the form of restricted share units with cliff vesting and a performance measure that must be achieved for the restricted share units to vest.
For employee recipients, in the event of termination of employment due to early retirement, with the consent of the Company, restricted shares and units granted within 12 months prior to termination are forfeited, and other restricted shares and units vest on a pro-rata basis, subject to the consent of the Compensation Committee. In the event of termination of employment due to normal retirement at age 65, restricted shares and units granted within 12 months prior to termination are forfeited, and, for other restricted shares and units, the restriction period applicable to restricted shares will lapse and the shares will vest and be transferable and all unvested units will become vested in full, subject to the consent of the Compensation Committee. In the event of a recipient's disability or death, all restricted shares and units granted within 12 months prior to termination fully vest. Termination for any other reason prior to the lapse of any restrictions or vesting of units results in forfeiture of the shares or units.
For non-employee directors, all restrictions lapse in the event of disability or death of the non-employee director. Termination of service as a director for any other reason within one year of date of grant results in a pro-rata vesting of shares or units.
As shares or units are issued, stock-based compensation equivalent to the fair value on the date of grant is expensed over the vesting period.
The following table summarizes activity related to restricted share units during the nine months ended July 31, 2025:

|  | Number of Units |  | Weighted-Average Grant Date Fair Value
Restricted share units at October 31, 2024 |  | 67 |  |  | $ | 238.83 |
Granted |  | 49 |  |  | 237.24
Forfeited |  | (9) |  |  | 228.11
Vested |  | (28) |  |  | 247.34
Restricted share units at July 31, 2025 |  | 79 |  |  | $ | 236.16 |

As of July 31, 2025, there was $11,336 of remaining expense to be recognized related to outstanding restricted share units, which is expected to be recognized over a weighted average period of 1.8 years. The amount charged to expense related to restricted share units during each of the three months ended July 31, 2025 and 2024 was $2,167 and $2,198, respectively, compared to charges of $7,028 and $6,658 for the nine months ended July 31, 2025 and 2024, respectively.
Performance Share Incentive Awards
Executive officers and selected other key employees are eligible to receive common share-based incentive awards. Payouts, in the form of unrestricted common shares, vary based on the degree to which corporate financial performance exceeds predetermined threshold, target and maximum performance goals over three-year performance periods. No payout will occur unless threshold performance is achieved.
The amount of compensation expense is based upon current performance projections and the percentage of the requisite service that has been rendered. The calculations are based upon the grant date fair value, which is principally driven by the stock price on the date of grant. The per share values were $199.30 in 2025, and $229.58 and $225.14 in 2024. The amount charged to expense related to performance awards for the three months ended July 31, 2025 and 2024 was $773 and $771, respectively. For the nine months ended July 31, 2025 and July 31, 2024, $3,507 and $3,637 were charged to expense, respectively. As of July 31, 2025, there was $8,304 of unrecognized compensation cost related to performance share incentive awards.
Deferred Compensation
Our executive officers and other highly compensated employees may elect to defer up to 100 percent of their base pay and cash incentive compensation, and for executive officers, up to 90 percent of their share-based performance incentive payout each year. Additional share units are credited for quarterly dividends paid on our common shares. Expense related to dividends paid under this plan for the three months ended July 31, 2025 and 2024 was $32 and $23, respectively, compared to $90 and $71 for the nine months ended July 31, 2025 and 2024, respectively.
Page 16

Table of Contents
Nordson Corporation
Deferred Directors' Compensation
Non-employee directors may defer all or part of their cash and equity-based compensation until retirement. Cash compensation may be deferred as cash or as share equivalent units. Deferred cash amounts are recorded as liabilities, and share equivalent units are recorded as equity. Additional share equivalent units are earned when common share dividends are declared.
The following table summarizes activity related to director deferred compensation share equivalent units during the nine months ended July 31, 2025:

|  | Number of Shares |  | Weighted-Average Grant Date Fair Value
Outstanding at October 31, 2024 |  | 65 |  |  | $ | 115.66 |
Restricted stock units vested and deferred fees |  | 1 |  |  | $ | 235.65 |
Dividend equivalents |  | 1 |  |  | 206.43
Distributions |  | (2) |  |  | 77.63 |
Outstanding at July 31, 2025 |  | 65 |  |  | $ | 120.67 |

T he amount charged to expense related to director deferred compensation for the three months ended July 31, 2025 and 2024 was $101 and $91, respectively, compared to $302 and $226 for the nine months ended July 31, 2025 and 2024, respectively.
Warranties
We offer warranties to our customers depending on the specific product and terms of the customer purchase agreement. A typical warranty program requires that we repair or replace defective products within a specified time period (generally one year) measured from the date of delivery or first use. We record an estimate for future warranty-related costs based on actual historical return rates. Based on analysis of return rates and other factors, the adequacy of our warranty provisions is adjusted as necessary. The liability for warranty costs is included in Accrued liabilities in the Consolidated Balance Sheets.
Following is a reconciliation of the product warranty liability for the nine months ended July 31, 2025 and 2024:

|  | July 31, 2025 |  | July 31, 2024
Beginning balance at October 31 |  | $ | 13,538 |  |  | $ | 14,401 |
Accruals for warranties |  | 9,796 |  |  | 10,841 |
Warranty payments |  | (8,482) |  |  | (11,279) |
Currency effect |  | 290 |  |  | (209) |
Ending balance |  | $ | 15,142 |  |  | $ | 13,754 |

Operating segments
We conduct business in three p rimary operating segments: IPS, MFS and ATS. The composition of segments and measure of segment profitability is consistent with that used by our chief operating decision maker. The primary measure us ed by the chief operating decision maker for purposes of making decisions about allocating resources to the segments and assessing performance is operating profit, which equals sales less cost of sales and certain operating expenses. Items below the operating profit line of the Condensed Consolidated Statements of Income (interest and investment income, interest expense and other income/expense) are excluded from the measure of segment profitability reviewed by our chief operating decision maker and are not presented by operating segment. The accounting policies of the segments are the same as those described in the Significant accounting policies Note.
Effective November 1, 2024, the MCS division was transferred from the IPS segment to the ATS segment due to an organizational change and determination that the economic and business characteristics of MCS better aligned with the Company’s ATS segment. Our segment reporting reflects this change and prior year financial information was revised to be comparable.
Industrial Precision Solutions: This segment focuses on delivering proprietary dispensing and processing technology, both standard and highly customized equipment, to diverse end markets. Product lines commonly reduce material consumption, increase line efficiency through precision dispensing, and enhance product brand and appearance. Components are used for
Page 17

Table of Contents
Nordson Corporation
dispensing adhesives, coatings, paint, finishes, sealants and other materials. This segment primarily serves the industrial, agricultural, consumer durables and non-durables markets.
Medical and Fluid Solutions: This segment includes the Company’s fluid management solutions for medical, high-tech industrial and other diverse end markets. Related plastic tubing, balloons, catheters, syringes, cartridges, tips and fluid connection components are used to dispense or control fluids within customers’ medical devices or products, as well as production processes.
Advanced Technology Solutions: This segment focuses on products serving electronics and consumer non-durable end markets. Advanced Technology Solutions products integrate our proprietary product technologies found in progressive stages of an electronics customer’s production and measurement and control processes, such as surface treatment, precisely controlled dispensing of material and test and inspection to ensure quality and reliability. Applications include, but are not limited to, semiconductors, printed circuit boards, electronic components, automotive electronics, in-line measurement sensors, gauges and analyzers.
The following table presents information about our segments:

Three Months Ended |  | Industrial Precision Solutions |  | Medical and Fluid Solutions |  | Advanced Technology Solutions |  | Corporate |  | Total
July 31, 2025 |  |  |  |  |  |  |  |  |  |
Net external sales |  | $ | 350,784 |  |  | $ | 219,465 |  |  | $ | 171,260 |  |  | $ | — |  |  | $ | 741,509 |
Operating profit (loss) |  | 116,720 |  |  | 52,500 |  |  | 36,877 |  |  | (18,330) |  |  | 187,767 |
July 31, 2024 |  |  |  |  |  |  |  |  |  |
Net external sales |  | $ | 348,997 |  |  | $ | 166,737 |  |  | $ | 145,870 |  |  | $ | — |  |  | $ | 661,604 |
Operating profit (loss) |  | 115,023 |  |  | 48,374 |  |  | 26,032 |  |  | (22,371) |  |  | 167,058 |
Nine Months Ended |  |  |  |  |  |  |  |  |  |
July 31, 2025 |  |  |  |  |  |  |  |  |  |
Net external sales |  | $ | 970,079 |  |  | $ | 615,883 |  |  | $ | 453,905 |  |  | $ | — |  |  | $ | 2,039,867 |
Operating profit (loss) |  | 308,153 |  |  | 150,241 |  |  | 86,558 |  |  | (47,488) |  |  | 497,464 |
July 31, 2024 |  |  |  |  |  |  |  |  |  |
Net external sales |  | $ | 1,031,717 |  |  | $ | 495,229 |  |  | $ | 418,493 |  |  | $ | — |  |  | $ | 1,945,439 |
Operating profit (loss) |  | 340,043 |  |  | 143,467 |  |  | 65,029 |  |  | (53,430) |  |  | 495,109 |

We had significant sales in the following geographic regions:

|  | Three Months Ended |  | Nine Months Ended
|  | July 31, 2025 |  | July 31, 2024 |  | July 31, 2025 |  | July 31, 2024
Americas |  | $ | 314,568 |  |  | $ | 287,016 |  |  | $ | 874,868 |  |  | $ | 855,456 |
Europe |  | 186,620 |  |  | 179,370 |  |  | 526,878 |  |  | 540,750 |
Asia Pacific |  | 240,321 |  |  | 195,218 |  |  | 638,121 |  |  | 549,233 |
Total net external sales |  | $ | 741,509 |  |  | $ | 661,604 |  |  | $ | 2,039,867 |  |  | $ | 1,945,439 |

Fair value measurements
The inputs to the valuation techniques used to measure fair value are classified into the following categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
Page 18

Table of Contents
Nordson Corporation
The following tables present the classification of our assets and liabilities measured at fair value on a recurring basis:

July 31, 2025 |  | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |  |
Foreign currency forward contracts (a) |  | $ | 4,274 |  |  | $ | — |  |  | $ | 4,274 |  |  | $ | — |
Interest rate swaps (b) |  | 8,662 |  |  | — |  |  | 8,662 |  |  | — |
Net investment contracts (c) |  | 4,153 |  |  | — |  |  | 4,153 |  |  | — |
Total assets at fair value |  | $ | 17,089 |  |  | $ | — |  |  | $ | 17,089 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |
Deferred compensation plans (d) |  | $ | 11,615 |  |  | $ | — |  |  | $ | 11,615 |  |  | $ | — |
Interest rate swaps (b) |  | 6 |  |  | — |  |  | 6 |  |  | — |
Net investment contracts (c) |  | 57,454 |  |  | — |  |  | 57,454 |  |  | — |
Foreign currency forward contracts (a) |  | 8,108 |  |  | — |  |  | 8,108 |  |  | — |
Total liabilities at fair value |  | $ | 77,183 |  |  | $ | — |  |  | $ | 77,183 |  |  | $ | — |

October 31, 2024 |  | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |  |
Foreign currency forward contracts (a) |  | $ | 3,332 |  |  | $ | — |  |  | $ | 3,332 |  |  | $ | — |
Net investment contracts (c) |  | 6,049 |  |  | — |  |  | 6,049 |  |  | — |
Total assets at fair value |  | $ | 9,381 |  |  | $ | — |  |  | $ | 9,381 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |
Deferred compensation plans (d) |  | $ | 9,615 |  |  | $ | — |  |  | $ | 9,615 |  |  | $ | — |
Net investment contracts (c) |  | 20,261 |  |  | — |  |  | 20,261 |  |  | — |
Foreign currency forward contracts (a) |  | 5,508 |  |  | — |  |  | 5,508 |  |  | — |
Total liabilities at fair value |  | $ | 35,384 |  |  | $ | — |  |  | $ | 35,384 |  |  | $ | — |

(a)We enter into foreign currency forward contracts to reduce the risk of foreign currency exposures resulting from receivables, payables, intercompany receivables, intercompany payables and loans denominated in foreign currencies. Foreign exchange contracts are valued using market exchange rates. These foreign exchange contracts are not designated as hedges.
(b)The Company is exposed to changes in the fair value of certain of its fixed-rate liabilities due to changes in benchmark interest rates. The Company uses interest rate swaps to manage its exposure to changes in fair value on these instruments attributable to changes in the designated benchmark interest rate, Secured Overnight Financing Rate ("SOFR"), with the objective of minimizing the cost of borrowed funds. The Company's interest rate swaps involve the receipt of fixed-rate amounts from a counterparty in exchange for the Company making variable-rate payments without the exchange of the underlying notional amount.
(c)Net assets of our foreign subsidiaries are exposed to volatility in foreign currency exchange rates. We utilize net investment hedges to offset the translation adjustment arising from re-measuring our investment in foreign subsidiaries. The fair value of these hedges is primarily based on the exchange rate between the currency pair of the hedge upon which settlement is based and includes an adjustment for the counterparty’s or Company’s credit risk. The notional amount of our net investment hedge contracts as of July 31, 2025 was $855,821.
(d)Executive officers and other highly compensated employees may defer up to 100% of their salary and annual cash incentive compensation and for executive officers, up to 90% of their long-term incentive compensation, into various non-qualified deferred compensation plans. Deferrals can be allocated to various market performance measurement funds. Changes in the value of compensation deferred under these plans are recognized each period based on the fair value of the underlying measurement funds.
The carrying amounts and fair values of financial instruments, other than cash and cash equivalents, receivables, accounts payable and notes payable, are shown in the table below. The carrying values of cash and cash equivalents, receivables, accounts payable and notes payable approximate fair value due to the short-term nature of these instruments.

|  | July 31, 2025
|  | Carrying Amount |  | Fair Value
Long-term debt (including current portion) |  | $ | 2,107,089 |  |  | $ | 2,143,866 |

Page 19

Table of Contents
Nordson Corporation
Long-term debt is valued by discounting future cash flows at currently available rates for borrowing arrangements with similar terms and conditions, which are considered to be Level 2 inputs under the fair value hierarchy. The carrying amount of long-term debt is shown net of unamortized debt issuance costs, bond discounts and interest rate swap fair value adjustment as disclosed in the Long-term debt Note.
Derivative financial instruments
The Company uses derivative instruments to manage foreign currency and interest rate risk as detailed below.
Foreign Currency Forward Contracts
We operate internationally and enter into intercompany transactions denominated in foreign currencies. Consequently, we are subject to market risk arising from exchange rate movements between the dates foreign currency transactions occur and the dates they are settled. We regularly use foreign currency forward contracts to reduce our risks related to most of these transactions. These contracts usually have maturities of 90 days or less and generally require us to exchange foreign currencies for U.S. dollars at maturity, at rates stated in the contracts. These contracts are not designated as hedging instruments under U.S. GAAP. Accordingly, the changes in the fair value of the foreign currency forward contracts are recognized in each accounting period in “Other – net” on the Condensed Consolidated Statements of Income together with the transaction gain or loss from the related balance sheet position. The settlement of these contracts is recorded in operating activities on the Condensed Consolidated Statement of Cash Flows.
For the three months ended July 31, 2025, we recognized a net loss of $19,609 on foreign currency forward contracts and a net gain of $16,568 from the change in fair value of balance sheet positions. For the three months ended July 31, 2024, we recognized a net gain of $2,954 on foreign currency forward contracts and a net loss of $3,418 from the change in fair value of balance sheet positions. For the nine months ended July 31, 2025, we recognized a net loss of $1,658 on foreign currency forward contracts and a net loss of $4,251 from the change in fair value of balance sheet positions. For the nine months ended July 31, 2024, we recognized a net gain of $8,624 on foreign currency forward contracts and a net loss of $11,035 from the change in fair value of balance sheet positions. The fair values of our foreign currency f orward contract assets and liabilities are included in Receivable-net and Accrued liabilities, respectively, in our Consolidated Balance Sheets.
The following table summarizes, by currency, the foreign currency forward contracts outstanding at July 31, 2025 and 2024:

July 31, 2025 contract amounts: |  | Notional Sell Amounts |  | Notional Buy Amounts
Euro |  | $ | 162,281 |  |  | $ | 263,630 |
British pound |  | 19,819 |  |  | 193,734 |
Japanese yen |  | 21,252 |  |  | 31,532 |
Mexican Peso |  | 3,413 |  |  | 32,467 |
Hong Kong dollar |  | 1,344 |  |  | 1,887 |
Singapore dollar |  | 600 |  |  | 27,122 |
Australian dollar |  | 1,100 |  |  | 10,111 |
Taiwan Dollar |  | — |  |  | 8,000 |
Others |  | 5,621 |  |  | 76,630 |
Total |  | $ | 215,430 |  |  | $ | 645,113 |
July 31, 2024 contract amounts: |  | Notional Sell Amounts |  | Notional Buy Amounts
Euro |  | $ | 124,144 |  |  | $ | 144,557 |
British pound |  | 17,187 |  |  | 138,240 |
Mexican Peso |  | 50 |  |  | 32,714 |
Japanese yen |  | 18,113 |  |  | 26,580 |
Hong Kong dollar |  | — |  |  | 1,942 |
Singapore dollar |  | 2,391 |  |  | 22,735 |
Australian dollar |  | — |  |  | 9,630 |
Taiwan Dollar |  | — |  |  | 8,000 |
Others |  | 3,425 |  |  | 71,755 |
Total |  | $ | 165,310 |  |  | $ | 456,153 |

Page 20

Table of Contents
Nordson Corporation
We are exposed to credit-related losses in the event of nonperformance by counterparties to financial instruments. These financial instruments include cash deposits and foreign currency forward contracts. We periodically monitor the credit ratings of these counterparties in order to minimize our exposure. Our customers represent a wide variety of industries and geographic regions. For the three and nine months ended July 31, 2025 and 2024, there were no significant concentrations of credit risk.
Treasury Locks
During the fourth quarter of 2024, the Company entered into treasury locks to fix the interest rate related to $250,000 of the $600,000 aggregate principal amount of 2029 Notes (as defined below) issued on September 4, 2024. The derivative positions were closed when the debt was priced on September 4, 2024 with a cash settlement net payment of $2,306 that offset changes in the benchmark treasury rate between execution of the treasury rate locks and the debt pricing date. These derivatives were designed as cash flow hedges and the deferred amount reported in AOCI is being reclassed to interest expense as payments are made on the notes through the maturity date.
Net Investment Hedges
Net assets of our foreign subsidiaries are exposed to volatility in foreign currency exchange rates. We may utilize net investment hedges to offset the translation adjustment arising from re-measuring our investment in foreign subsidiaries.
As of July 31, 2025, the Company was party to various cross currency swaps between the U.S. Dollar and Euro, Japanese Yen, Taiwan Dollar, Singapore Dollar and Chinese Yuan, which were designated as hedges of our net investments in certain foreign subsidiaries to mitigate the foreign exchange risk associated with certain investments in these subsidiaries. Any increases or decreases related to the remeasurement of the hedges are recorded in the currency translation component of Accumulated other comprehensive income (loss) within Shareholders' Equity in the Consolidated Balance Sheet until the sale or substantial liquidation of the underlying investments. A loss of $6,868 and a loss of $27,470, net of tax, was recorded for the three and nine months ended July 31, 2025, respectively, compared to a loss of $6,968 and a loss of $11,475, net of tax, for the three and nine months ended July 31, 2024, respectively.
The following table summarizes the fair values of our net investment contracts designated as net investment hedges in the Company's Condensed Consolidated Balance Sheets as of July 31, 2025:

|  | Prepaid expenses and other current assets |  | Other assets |  | Accrued liabilities |  | Other long-term liabilities
Net investment contracts |  | $ | 4,153 |  |  | $ | — |  |  | $ | 332 |  |  | $ | 57,122 |

Fair Value Hedges of Interest Rate Risk
The Company is exposed to changes in the fair value of certain of its fixed-rate liabilities due to changes in benchmark interest rates. The Company uses interest rate swaps to manage its exposure to changes in fair value on these instruments attributable to changes in the designated benchmark interest rate, SOFR, with the objective of minimizing the cost of borrowed funds. The Company's interest rate swaps involve the receipt of fixed-rate amounts from a counterparty in exchange for the Company making variable-rate payments without the exchange of the underlying notional amount.
The Company's interest rate swaps are designated and qualify as fair value hedges. As a result, the interest rate swaps are measured at fair value and the carrying value of the hedged debt is adjusted for the change in value related to the exposure being hedged, with both adjustments offset to earnings. Accordingly, the earnings effect of an increase in the fair value of the interest rate swaps will be substantially offset by the earnings effect of the increase in the carrying value of the hedged debt. The net impact of fair value hedge accounting for interest rate swaps is recognized in Interest expense. A loss of $136 and a loss of $209, net of tax, was recorded for the three and nine months ended July 31, 2025, respectively. The fair values of our interest rate swap assets are included in Prepaid expenses and other current assets and Other assets in our Consolidated Balance Sheets.
The following table provides information regarding the Company's outstanding interest rate derivatives that were used to hedge changes in fair value attributable to interest rate risk:

|  | Interest rate swaps - notional amount |  | Cumulative adjustment to long-term debt from application of hedge accounting |  | Carrying value of hedged debt |  |
Interest rate swaps |  | $ | 300,000 |  |  | $ | 8,656 |  |  | $ | 308,656 |  |  |

Page 21

Table of Contents
Nordson Corporation
Long-term debt
A summary of long-term debt is as follows:

|  | July 31, 2025 |  | October 31, 2024
Notes Payable |  | $ | 6,078 |  |  | $ | 18,285 |
Revolving credit agreement, due 2028 |  | 243,000 |  |  | 240,000 |
Term loan due 2026 |  | 280,000 |  |  | 280,000 |
Senior notes, due 2025 |  | — |  |  | 8,500 |
Senior notes, due 2025-2027 |  | 20,000 |  |  | 37,143 |
Senior notes, due 2025-2030 |  | 130,000 |  |  | 190,000 |
5.600% Notes due 2028 |  | 350,000 |  |  | 350,000 |
5.800% Notes due 2033 |  | 500,000 |  |  | 500,000 |
4.500% Notes due 2029 |  | 600,000 |  |  | 600,000 |
|  | 2,129,078 |  |  | 2,223,928 |
Less current maturities |  | 336,078 |  |  | 103,928 |
Less unamortized debt issuance costs |  | 13,751 |  |  | 16,359 |
Less bond discounts |  | 2,160 |  |  | 2,444 |
Plus impact of interest rate swaps |  | 8,656 |  |  | — |
Long-term maturities |  | $ | 1,785,745 |  |  | $ | 2,101,197 |

Revolving credit agreement — In June 2023, we entered into a $1,150,000 unsecured multi-currency credit facility with a group of banks, which provides for a term loan facility in the aggregate principal amount of $300,000 (the "Term Loan Facility"), maturing in June 2026, and a multicurrency revolving credit facility in the aggregate principal amount of $850,000 (the "Revolving Facility"), maturing in June 2028 (the "New Credit Agreement"). In June 2024, the Revolving Facility was amended to increase the aggregate principal amount to $922,500. The Company borrowed and has outstanding $280,000 on the Term Loan Facility and $243,000 on the Revolving Facility as of July 31, 2025. The Revolving Facility permits borrowing in U.S. Dollars, Euros, Sterling, Swiss Francs, Singapore Dollars, Yen, and each other currency approved by a Revolving Facility lender. The New Credit Agreement provides that the applicable margin for (i) Risk-Free Rate ("RFR"), as defined in the New Credit Agreement, and Eurodollar Loans will range from 0.85% to 1.20% and (ii) Base Rate Loans will range from 0.00% to 0.20%, in each case, based on the Company’s Leverage Ratio (as defined in the New Credit Agreement and calculated on a consolidated net debt basis). Borrowings under the New Credit Agreement bear interest at (i) either a base rate or a SOFR rate, with respect to borrowings in U.S. dollars, (ii) a eurocurrency rate, with respect to borrowings in Euros and Yen, or (iii) Daily Simple RFR, with respect to borrowings in Sterling, Swiss Francs or Singapore Dollars, plus, in each case, an applicable margin (and, solely in the case of Singapore Dollars, a spread adjustment). The applicable margin is based on the Company’s Leverage Ratio. The weighted-average interest rate at July 31, 2025 was 5.48%.
Senior notes, due 2025 — These unsecured fixed-rate notes entered into in 2012 with a group of insurance companies were paid off in July of 2025.
Senior notes, due 2025-2027 — These unsecured fixed-rate notes entered into in 2015 with a group of insurance companies have a remaining weighted-average life of 1.49 years. The weighted-average interest rate at July 31, 2025 was 3.19%.
Senior notes, due 2025-2030 — These unsecured fixed-rate notes entered into in 2018 with a group of insurance companies have a remaining weighted-average life of 2.90 years. The weighted-average interest rate at July 31, 2025 was 4.08%.
5.600% Notes due 2028 and 5.800% Notes due 2033 — In September 2023, we completed an underwritten public offering of $350,000 aggregate principal amount of 5.600% Notes due 2028 and $500,000 aggregate principal amount of 5.800% Notes due 2033.
4.500% Notes due 2029 — In September 2024, we completed an underwritten public offering of $600,000 aggregate principal amount of 4.500% Notes due 2029 (the "2029 Notes").
We were in compliance with all covenants at July 31, 2025, and the amount we could borrow would not have been limited by any debt covenants.
Page 22

Table of Contents
Nordson Corporation
Contingencies
We are involved in pending or potential litigation regarding environmental, product liability, patent, contract, employee and other matters arising from the normal course of business. Including the environmental matter discussed below, after consultation with legal counsel, we do not believe that losses in excess of the amounts we have accrued would have a material adverse effect on our financial condition, quarterly or annual operating results or cash flows.
Environmental
We have voluntarily agreed with the City of New Richmond, Wisconsin and other potentially responsible parties to share costs associated with the remediation of the City of New Richmond municipal landfill (the “Site”) and the construction of a potable water delivery system serving the impacted area down gradient of the Site. As of July 31, 2025 and October 31, 2024, our accrual for the ongoing operation, maintenance and monitoring obligation at the Site was immaterial. The liability for environmental remediation represents management’s best estimate of the probable and reasonably estimable undiscounted costs related to known remediation obligations. The accuracy of our estimate of environmental liability is affected by several uncertainties such as additional requirements that may be identified in connection with remedial activities, the complexity and evolution of environmental laws and regulations, and the identification of presently unknown remediation requirements. Consequently, our liability could be greater than our current estimate. However, we do not expect that the costs associated with remediation will have a material adverse effect on our financial condition or results of operations.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following is management's discussion and analysis of certain significant factors affecting our financial condition and results of operations for the periods included in the accompanying condensed consolidated financial statements. Throughout this Quarterly Report on Form 10-Q, components may not sum to totals due to rounding.
Overview
Nordson is an innovative precision technology company that leverages a scalable growth framework expected to deliver top tier growth with leading margins and returns. We engineer, manufacture and market differentiated products and systems used for precision dispensing, applying and controlling of adhesives, coatings, polymers, sealants, biomaterials, and other fluids, to test and inspect for quality, and to treat and cure surfaces and various medical products such as: catheters, cannulas, medical balloons and medical tubing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, electronics, medical, appliances, energy, transportation, precision agriculture, building and construction, and general product assembly and finishing.
Our strategy for long-term growth is based on solving customers’ needs globally. We were incorporated in the State of Ohio in 1954 and are headquartered in Westlake, Ohio. Our products are marketed through a network of direct operations in more than 35 countries.
As of July 31, 2025, we had approximately 7,700 employees worldwide. We have principal manufacturing operations and sources of supply in the United States in Ohio, Georgia, California, Colorado, Connecticut, Illinois, Michigan, Minnesota, Pennsylvania, Rhode Island, Tennessee, Florida, Texas, Alabama, South Carolina and Wisconsin; as well as in the People’s Republic of China, Germany, Ireland, India, Israel, Italy, Mexico, the Netherlands and the United Kingdom.
Critical Accounting Policies and Estimates
A comprehensive discussion of the Company’s critical accounting policies and management estimates and significant accounting policies followed in the preparation of the financial statements is included in Item 7 of our Annual Report on Form 10-K for the year ended October 31, 2024 (the "2024 Form 10-K"). There have been no significant changes in critical accounting policies, management estimates or accounting policies followed since the year ended October 31, 2024.
Page 23

Table of Contents
Nordson Corporation
Results of Operations
Below is a detailed comparison of our results of operations for the three and nine months ended July 31, 2025 and July 31, 2024.
As used throughout this Quarterly Report on Form 10-Q, geographic regions include the Americas (United States, Canada, Mexico and Central and South America), Asia Pacific and Europe.
Consolidated Financial Results
Consolidated financial results for the three months ended July 31, 2025 and July 31, 2024 were as follows:

|  | Three Months Ended |  |
(In thousands except for per-share amounts) |  | July 31, 2025 |  | July 31, 2024 |  | Change
Sales |  | $ | 741,509 |  |  | $ | 661,604 |  |  | 12.1 | %
Cost of sales |  | 334,992 |  |  | 292,603 |  |  | 14.5 | %
Gross margin |  | 406,517 |  |  | 369,001 |  |  | 10.2 | %
Gross margin % |  | 54.8 | % |  | 55.8 | % |  | (1.0) | %
Selling and administrative expenses |  | 206,539 |  |  | 201,943 |  |  | 2.3 | %
Divestiture and related charges |  | 12,211 |  |  | — |  |  | 100.0 | %
Operating profit |  | 187,767 |  |  | 167,058 |  |  | 12.4 | %
Interest expense |  | (26,258) |  |  | (18,803) |  |  | 39.6 | %
Interest and investment income |  | 560 |  |  | 1,027 |  |  | (45.5) | %
Other - net |  | (2,945) |  |  | 152 |  |  | (2037.5) | %
Income before income taxes |  | 159,124 |  |  | 149,434 |  |  | 6.5 | %
Income tax expense |  | 33,340 |  |  | 32,107 |  |  | 3.8 | %
Net income |  | $ | 125,784 |  |  | $ | 117,327 |  |  | 7.2 | %

Consolidated financial results for the nine months ended July 31, 2025 and July 31, 2024 were as follows:

|  | Nine Months Ended |  |
(In thousands except for per-share amounts) |  | July 31, 2025 |  | July 31, 2024 |  | Change
Sales |  | $ | 2,039,867 |  |  | $ | 1,945,439 |  |  | 4.9 | %
Cost of sales |  | 923,550 |  |  | 862,134 |  |  | 7.1 | %
Gross margin |  | 1,116,317 |  |  | 1,083,305 |  |  | 3.0 | %
Gross margin % |  | 54.7 | % |  | 55.7 | % |  | (1.0) | %
Selling and administrative expenses |  | 606,642 |  |  | 588,196 |  |  | 3.1 | %
Divestiture and related charges |  | 12,211 |  |  | — |  |  | 100.0 | %
Operating profit |  | 497,464 |  |  | 495,109 |  |  | 0.5 | %
Interest expense |  | (79,389) |  |  | (60,354) |  |  | 31.5 | %
Interest and investment income |  | 2,054 |  |  | 3,625 |  |  | (43.3) | %
Other - net |  | (5,380) |  |  | (971) |  |  | 454.1 | %
Income before income taxes |  | 414,749 |  |  | 437,409 |  |  | (5.2) | %
Income tax expense |  | 81,909 |  |  | 92,293 |  |  | (11.3) | %
Net income |  | $ | 332,840 |  |  | $ | 345,116 |  |  | (3.6) | %

Page 24

Table of Contents
Nordson Corporation
Net Sales
Net sales for the IPS, MFS and ATS segments were as follows:

| Three Months Ended |  | Variance - Increase (Decrease) |
| Jul 31, 2025 | % of Total | Jul 31, 2024 | % of Total |  | Organic |  | Acquisitions |  | Currency |  | Total |
IPS | $ | 350,784 |  | 47.3% | $ | 348,997 |  | 52.8% |  | (2.0) | % |  | — | % |  | 2.5 | % |  | 0.5 | % |
MFS | 219,465 |  | 29.6% | 166,737 |  | 25.2% |  | (0.4) | % |  | 31.0 | % |  | 1.0 | % |  | 31.6 | % |
ATS | 171,260 |  | 23.1% | 145,870 |  | 22.0% |  | 14.6 | % |  | — | % |  | 2.8 | % |  | 17.4 | % |
Total | $ | 741,509 |  |  | $ | 661,604 |  |  |  | 2.1 | % |  | 7.8 | % |  | 2.2 | % |  | 12.1 | % |
| Nine Months Ended |  | Variance - Increase (Decrease) |
| Jul 31, 2025 | % of Total | Jul 31, 2024 | % of Total |  | Organic |  | Acquisitions |  | Currency |  | Total |
IPS | $ | 970,079 |  | 47.6% | $ | 1,031,717 |  | 53.0% |  | (5.7) | % |  | — | % |  | (0.3) | % |  | (6.0) | % |
MFS | 615,883 |  | 30.2% | 495,229 |  | 25.5% |  | (7.1) | % |  | 31.5 | % |  | — | % |  | 24.4 | % |
ATS | 453,905 |  | 22.2% | 418,493 |  | 21.5% |  | 8.0 | % |  | — | % |  | 0.5 | % |  | 8.5 | % |
Total | $ | 2,039,867 |  |  | $ | 1,945,439 |  |  |  | (3.1) | % |  | 8.1 | % |  | (0.1) | % |  | 4.9 | % |

Three Months Ended July 31, 2025
The IPS organic sales decrease of 2.0 percent was driven by weaker systems demand in polymer processing partially offset by broad based growth in most other product lines. MFS organic sales decreased 0.4 percent inclusive of the contract manufacturing business that is held for sale. Excluding the pending divestiture in both periods, organic sales increased 4 percent driven by medical fluid components and fluid solutions product lines. The inorganic growth of MFS is due to the acquisition of Atrion. The ATS organic sales increase of 14.6 percent was driven by robust growth in electronics dispense product lines, offset by weakness in x-ray inspections systems.
Nine Months Ended July 31, 2025
The IPS organic sales decrease of 5.7 percent was driven primarily by weaker systems demand in polymer processing and industrial coatings product lines, which was partially offset by broad based growth in most other product lines. MFS organic sales decreased 7.1 percent inclusive of the contract manufacturing business that is held for sale. Excluding the pending divestiture in both periods, organic sales decreased 2.3 percent driven by lower demand and tough year-over-year comparisons in medical interventional solutions product lines, where customer destocking trends continued to impact demand. The ATS organic sales increase of 8.0 percent was driven by robust growth in electronics dispense product lines and electronic processing and optical sensors, partially offset by weakness in x-ray inspection systems and the measurement and control product line.
Net Sales by region were as follows:

| Three Months Ended |  | Variance - Increase (Decrease)
| Jul 31, 2025 | % of Total | Jul 31, 2024 | % of Total |  | Organic |  | Acquisitions |  | Currency |  | Total
Americas | $ | 314,568 |  | 42.4% | $ | 287,016 |  | 43.4% |  | (3.2) | % |  | 13.0 | % |  | (0.2) | % |  | 9.6 | %
Europe | 186,620 |  | 25.2% | 179,370 |  | 27.1% |  | (6.1) | % |  | 4.8 | % |  | 5.3 | % |  | 4.0 | %
Asia Pacific | 240,321 |  | 32.4% | 195,218 |  | 29.5% |  | 17.4 | % |  | 2.9 | % |  | 2.8 | % |  | 23.1 | %
Total | $ | 741,509 |  |  | $ | 661,604 |  |  |  | 2.1 | % |  | 7.8 | % |  | 2.2 | % |  | 12.1 | %
| Nine Months Ended |  | Variance - Increase (Decrease)
| Jul 31, 2025 | % of Total | Jul 31, 2024 | % of Total |  | Organic |  | Acquisitions |  | Currency |  | Total
Americas | $ | 874,868 |  | 42.9% | $ | 855,456 |  | 44.0% |  | (10.0) | % |  | 13.1 | % |  | (0.8) | % |  | 2.3 | %
Europe | 526,878 |  | 25.8% | 540,750 |  | 27.8% |  | (8.7) | % |  | 5.0 | % |  | 1.1 | % |  | (2.6) | %
Asia Pacific | 638,121 |  | 31.3% | 549,233 |  | 28.2% |  | 13.1 | % |  | 3.1 | % |  | — | % |  | 16.2 | %
Total | $ | 2,039,867 |  |  | $ | 1,945,439 |  |  |  | (3.1) | % |  | 8.1 | % |  | (0.1) | % |  | 4.9 | %

Page 25

Table of Contents
Nordson Corporation
Operating Profit
Operating profit for the IPS, MFS and ATS segments were as follows:

| Three Months Ended |  |  |  |  |  |  |
| Jul 31, 2025 | % of Sales | Jul 31, 2024 | % of Sales |  | % of Sales Change |  | Increase (Decrease)
IPS | $ | 116,720 |  | 33.3% | $ | 115,023 |  | 33.0% |  | 0.3% |  | $ | 1,697 |  |  | 1.5 | % |
MFS | 52,500 |  | 23.9% | 48,374 |  | 29.0% |  | (5.1)% |  | 4,126 |  |  | 8.5 | % |
ATS | 36,877 |  | 21.5% | 26,032 |  | 17.8% |  | 3.7% |  | 10,845 |  |  | 41.7 | % |
Corporate | (18,330) |  |  | (22,371) |  |  |  |  |  | 4,041 |  |  | 18.1 | % |
Total | $ | 187,767 |  | 25.3% | $ | 167,058 |  | 25.3% |  | —% |  | $ | 20,709 |  |  | 12.4 | % |
| Nine Months Ended |  |  |  |  |  |  |
| Jul 31, 2025 | % of Sales | Jul 31, 2024 | % of Sales |  | % of Sales Change |  | Increase (Decrease)
IPS | $ | 308,153 |  | 31.8% | $ | 340,043 |  | 33.0% |  | (1.2)% |  | $ | (31,890) |  |  | (9.4) | % |
MFS | 150,241 |  | 24.4% | 143,467 |  | 29.0% |  | (4.6)% |  | 6,774 |  |  | 4.7 | % |
ATS | 86,558 |  | 19.1% | 65,029 |  | 15.5% |  | 3.6% |  | 21,529 |  |  | 33.1 | % |
Corporate | (47,488) |  |  | (53,430) |  |  |  |  |  | 5,942 |  |  | 11.1 | % |
Total | $ | 497,464 |  | 24.4% | $ | 495,109 |  | 25.4% |  | (1.0)% |  | $ | 2,355 |  |  | 0.5 | % |

Three Months Ended July 31, 2025
IPS operating margin increased 30 basis points on flat sales volume, driven by lower restructuring costs. MFS operating margin declined 510 basis points. Excluding restructuring, costs related to the Atrion acquisition and charges associated with the exit of the medical contract manufacturing business, operating margin increased 80 basis points reflecting increased leverage of selling and administrative expenses in the core business, as well as contribution from the Atrion acquisition. ATS operating margin improved by 37 0 basis points driven by strong conversion on increased organic sales and the benefits of strategic cost reduction actions and manufacturing footprint optimization.
Nine Months Ended July 31, 2025
I PS operating margin declined 12 0 basis points due to lower sales volumes. M FS operating margin declined 460 basis points. Excluding restructuring costs related to the Atrion acquisition and charges associated with the exit of the medical contract manufacturing business, operating margin decreased 140 basis points reflecting lower organic sales demand partially offset by the impact of the Atrion acquisition. ATS operating m argin improved by 360 basis points driven by strong organic sales growth and the benefits of strategic cost reduction actions and manufacturing footprint optimization.
Interest expense and Other-net
Interest expense for the three months ended July 31, 2025 was $26,258, compared to $18,803 in the comparable period of 2024. The increase, compared to the prior year period, was primarily due to higher average debt levels, driven by acquisitions. Other-net for the three months ended July 31, 2025 was expense of $2,945 compared to income of $152 in the comparable period of 2024. Included in other-net for the three months ended July 31, 2025 were pension and postretirement income of $1,008 and $3,041 of foreign currency losses. Included in other-net for the three months ended July 31, 2024 were pension and postretirement income of $1,028 and $464 in foreign currency losses.
Interest expense for the nine months ended July 31, 2025 was $79,389, compared to $60,354 in the comparable period of 2024. The increase, compared to the prior year period, was primarily due to higher average debt levels, driven by acquisitions. Other-net was expense of $5,380 compared to expense of $971 in the comparable period of 2024. Included in other-net for the nine months ended July 31, 2025 were pension and postretirement income of $3,042 and $5,909 o f foreign currency losses. Included in other-net for the nine months ended July 31, 2024 were pension and postretirement income of $3,085 and $2,411 in foreign currency losses.
Income Tax Expense
We record our interim provision for income taxes based on our estimated annual effective tax rate, as well as certain items discrete to the current period. Significant judgment is involved regarding the application of global income tax laws and regulations and when projecting the jurisdictional mix of income. We have considered several factors in determining the probability of realizing deferred income tax assets including forecasted operating earnings, available tax planning strategies and
Page 26

Table of Contents
Nordson Corporation
the time period over which the temporary differences will reverse. We review our tax positions on a regular basis and adjust the balances as new information becomes available. The effective tax rates for both the three and nine months ended July 31, 2025 were 21.0% and 19.7%, respectively, compared to 21.5% and 21.1%, respectively, for the same periods in 2024. Excluding a discrete tax impact related to the divestiture and related charges taken in the third quarter of 2025, the effective tax rates for the three and nine months ended July 31, 2025 were 19.4% and 19.2%, respectively. The effective tax rate for the nine months ended July 31, 2025 is lower than the U.S. tax rate of 21% primarily due to the foreign-derived intangible income deduction.
Net Income
Net income was $125,784, or $2.22 per diluted share, for the three months ended July 31, 2025, compared to net income of $117,327, or $2.04 per diluted share, in the same period of 2024. This represented a 7.2 percent increase in net income and a 8.8 percent increase in diluted earnings per share. The increase in net income and increase of $0.18 per diluted share was primarily driven by higher operating profit, partially offset by higher interest expense due to prior year's acquisitions and the divestiture and related charges associated with exiting the medical contract manufacturing business.
Net income was $332,840, or $5.83 per diluted share, for the nine months ended July 31, 2025, compared to net income of $345,116, or $5.99 per diluted share, in the same period of 2024. This represented a 3.6 percent decrease in net income and a 2.7 percent decrease in diluted earnings per share. The decrease in net income and decrease of $0.16 per diluted share was primarily driven by higher interest expense due to prior year's acquisition and the divestiture and related charges associated with exiting the medical contract manufacturing business.
Foreign Currency Effects
It is not possible to precisely measure the impact on operating results arising from foreign currency exchange rate changes, because of changes in selling prices, sales volume, product mix and cost structure in each country in which we operate. However, if transactions for the three months ended July 31, 2025 were translated at exchange rates in effect during the same period of 2024, we estimated that sales would have been approximately $13,000 lower while costs of sales and selling and administrative expenses would have been approximately $8,000 lower. If transactions for the nine months ended July 31, 2025 were translated at exchange rates in effect during the same period of 2024, we estimated that sales would have been approximately $3,000 higher while costs of sales and selling and administrative expenses would have been approximately $500 lower.
Other Trends
Changes in trade policies, tariffs, and other import/export regulations of the U.S. and other nations did not have a material impact on our financial results for the nine months ended July 31, 2025. However, the Company does have sales and purchases that could be negatively impacted by recent tariff actions. The Company continues to actively work to minimize the impact of these changes and mitigate risk.
Page 27

Table of Contents
Nordson Corporation
Financial Condition
Liquidity and Capital Resources
Cash and cash equivalents increased $31,836 during the nine months ended July 31, 2025. Approximately 82 percent of our consolidated cash and cash equivalents were held at various foreign subsidiaries as of July 31, 2025.
A comparison of cash flow changes for the nine months ended July 31, 2025 to the nine months ended July 31, 2024 is as follows:

| Nine Months Ended |  |
| July 31, 2025 |  | July 31, 2024 |  | Increase (Decrease)
Net Income and non-cash items | $ | 469,659 |  |  | $ | 460,197 |  |  | $ | 9,462 |
Changes in operating assets and liabilities | 46,605 |  |  | (385) |  |  | 46,990 |
Net cash provided by operating activities | 516,264 |  |  | 459,812 |  |  | 56,452 |
Additions to property, plant and equipment | (49,002) |  |  | (43,786) |  |  | (5,216) |
Other - net | 4,272 |  |  | 8,896 |  |  | (4,624) |
Net cash used in investing activities | (44,730) |  |  | (34,890) |  |  | (9,840) |
Payments of long-term debt - net | (94,664) |  |  | (244,355) |  |  | 149,691 |
Repayment of finance lease obligations | (4,083) |  |  | (4,505) |  |  | 422 |
Dividends paid | (133,008) |  |  | (116,789) |  |  | (16,219) |
Issuance of common shares | 5,419 |  |  | 29,142 |  |  | (23,723) |
Purchase of treasury shares | (218,194) |  |  | (34,105) |  |  | (184,089) |
Net cash used in financing activities | $ | (444,530) |  |  | $ | (370,612) |  |  | $ | (73,918) |

Additions to property, plant and equipment were largely driven by productivity and growth projects, including a new manufacturing facility.
We have a $1,150,000 unsecured multi-currency credit facility with a group of banks that provides for a term loan facility in the aggregate principal amount of $300,000, maturing in June 2026, and a multicurrency revolving credit facility in the aggregate principal amount of $850,000, maturing in June 2028. At July 31, 2025, we had $280,000 outstanding on the term loan facility and $243,000 outstanding on the revolving credit facility.
Our operating performance, balance sheet position and financial ratios for nine months ended July 31, 2025 remained strong. The Company is well-positioned to manage liquidity needs that arise from working capital requirements, capital expenditures and contributions related to pension and postretirement obligations, as well as principal and interest payments on our outstanding debt. Our primary sources of capital to meet these needs, as well as other opportunistic investments, are a combination of cash on hand, which was $147,788 as of July 31, 2025, cash provided by operations, which was $516,264 for the nine months ended July 31, 2025, and available borrowings under our loan agreements and unused bank lines of credit, which totaled $824,120 as of July 31, 2025. Cash from operations, which, when combined with our available borrowing capacity and ready access to capital markets, is expected to be more than adequate to fund our liquidity needs over the twelve months and the foreseeable future thereafter. The Company believes it has the ability to generate and obtain adequate amounts of cash to meet its long-term needs for cash. However, the impact of changes in trade policies, tariffs, and other import/export regulations of the U.S. and other nations could negatively impact our cash flow from operations and liquidity in future periods.
Page 28

Table of Contents
Nordson Corporation
Safe Harbor Statements Under the Private Securities Litigation Reform Act of 1995
This Quarterly Report on Form 10-Q, particularly “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. Such statements relate to, among other things, income, earnings, cash flows, changes in operations, operating improvements, businesses in which we operate and the United States and global economies. Statements in this Quarterly Report on Form 10-Q that are not historical are hereby identified as “forward-looking statements” and may be indicated by words or phrases such as “anticipates,” “supports,” “plans,” “projects,” “expects,” “believes,” “should,” “would,” “could,” “hope,” “forecast,” “management is of the opinion,” use of the future tense and similar words or phrases. These forward-looking statements reflect management’s current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic and political conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions and the Company’s ability to complete and successfully integrate acquisitions, including the integration of Atrion; the Company’s ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements, including changes in tariffs by the U.S. or other nations; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflicts in Europe and the Middle East, acts of terror, natural disasters and pandemics.
In light of these risks and uncertainties, actual events and results may vary significantly from those included in or contemplated or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Factors that could cause our actual results to differ materially from the expected results are discussed in Part I, Item 1A, Risk Factors in our 2024 Form 10-K and Part II, Item 1A, Risk Factors in the Quarterly Report on Form 10-Q.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Information regarding our financial instruments that are sensitive to changes in interest rates and foreign currency exchange rates was disclosed under Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” in our 2024 Form 10-K. The information disclosed has not changed materially in the interim period since then.
ITEM 4. CONTROLS AND PROCEDURES
Our management with the participation of the principal executive officer (president and chief executive officer) and principal financial officer (executive vice president and chief financial officer) has reviewed and evaluated our disclosure controls and procedures (as defined in the Exchange Act Rule 13a-15(e)) as of July 31, 2025. Based on that evaluation, our management, including the principal executive and financial officers, has concluded that our disclosure controls and procedures were effective as of July 31, 2025 in ensuring that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
There were no changes in our internal control over financial reporting that occurred during the three months ended July 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Page 29

Table of Contents
Nordson Corporation
Part II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
See our Contingencies Note to the condensed consolidated financial statements for a discussion of our contingencies and legal matters.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors disclosed in “Item 1A. Risk Factors” of our 2024 Form 10-K. Other than as set forth below, there have been no material changes to the risk factors described in the 2024 Form 10-K.
Changes to trade policies, tariffs, and other import/export regulations of the U.S. and other nations may create uncertainty in the global market and have a material adverse effect on our business, financial condition, and results of operations.
Changes in trade policies, tariffs, and other import/export regulations of the U.S. and other nations could change how we transact business, who we trade with, affect our relationships with customers and suppliers, and negatively impact our sales, margins and profitability. As a result, these government trade actions may create significant uncertainty in the global market and may have a material adverse impact on our business, financial condition and results of operations.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table summarizes common shares repurchased by the Company during the three months ended July 31, 2025:

(In whole shares) |  | Total Number of Shares Repurchased (1) |  | Average Price Paid per Share |  | Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs (2) |  | Maximum Value of Shares that May Yet Be Purchased Under the Plans or Programs (2)
May 1, 2025 to May 31, 2025 |  | 79,778 |  |  | $ | 194.13 |  |  | 79,663 |  |  | $ | 367,085 |
June 1, 2025 to June 30, 2025 |  | 116,187 |  |  | $ | 215.52 |  |  | 115,956 |  |  | $ | 342,094 |
July 1, 2025 to July 31, 2025 |  | 140,403 |  |  | $ | 219.04 |  |  | 140,160 |  |  | $ | 311,394 |
Total |  | 336,368 |  |  | $ | 211.92 |  |  | 335,779 |  |  | $ | 311,394 |

(1) Includes shares tendered for taxes related to stock option exercises and vesting of restricted stock.
(2) In December 2014, the board of directors authorized a $300,000 common share repurchase program. In August 2015, the board of directors authorized the repurchase of up to an additional $200,000 of the Company’s common shares. In August 2018, the board of directors authorized the repurchase of an additional $500,000 of the Company’s common shares. In September 2022, the board of directors authorized the repurchase of up to an additional $500,000 of the Company's common shares. Approximately $311,394 of the total $1,500,000 authorized remained available for share repurchases at July 31, 2025. In August 2025, the board of directors authorized the repurchase of an additional $500,000 of the Company’s common shares. Uses for repurchased shares include the funding of benefit programs including stock options and restricted stock. Shares purchased are treated as treasury shares until used for such purposes. The repurchase program will be funded using cash from operations and proceeds from borrowings under our credit facilities. The repurchase program does not have an expiration date.
Page 30

Table of Contents
Nordson Corporation
ITEM 5. OTHER INFORMATION
During the quarter ended July 31, 2025, no director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K, except as described in the table below:

Trading Arrangement
| Action | Action Date | Rule 10b5-1 1 | Non-Rule 10b5-1 2 | Total Shares to be Sold | Expiration Date
Stephen P. Lovass, Executive Vice President | Terminated 3 | 6/1/2025 | x |  | Up to 2,237 shares | 1/16/2026
1 Intended to satisfy the affirmative defense of Rule 10b5-1(c)
2 Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
3 The trading arrangement was terminated in connection with Mr. Lovass' separation from the Company, effective June 1, 2025.

ITEM 6. | EXHIBITS

10.1 | Separation agreement between Stephen Lovass and Nordson Corporation, effective June 1, 2025
31.1 | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 by the Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 by the Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
101 | The following financial information from Nordson Corporation’s Quarterly Report on Form 10-Q for the three and nine months ended July 31, 2025 formatted in inline Extensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Statements of Income for the three and nine months ended July 31, 2025 and 2024, (ii) the Consolidated Statements of Comprehensive Income for the three and nine months ended July 31, 2025 and 2024, (iii) the Consolidated Balance Sheets at July 31, 2025 and October 31, 2024, (iv) the Consolidated Statements of Shareholders’ Equity for the three and nine months ended July 31, 2025 and 2024, (v) the Condensed Consolidated Statements of Cash Flows for the nine months ended July 31, 2025 and 2024, and (vi) the Notes to Condensed Consolidated Financial Statements.
104 | The cover page from Nordson Corporation’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2025, formatted in inline Extensible Business Reporting Language (iXBRL) (included in Exhibit 101).

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 21, 2025 | Nordson Corporation
| /s/ Joseph Rutledge
| Joseph Rutledge
| Chief Accounting Officer

Page 31